

Curriculum Vitae, Wil Milhous, 2014

WILBUR KEARSE MILHOUS

Professor and Associate Dean for Research
College of Public Health • University of South Florida
13201 Bruce B. Downs Boulevard, MDC56, Tampa, FL 33612 • Ph: (813) 396-9065 • Fax: (813)974-0959
Email: wmilhous@health.usf.edu
Global Health Infectious Disease Research (GHIDR) Program
Interdisciplinary Research Building (IDRB) • 3720 Spectrum Blvd, Suite 304, Tampa, FL 33612

Personal Information

Married: Virginia Graves Milhous
Children: Elizabeth E. Milhous and Allyson Milhous Best
Grandchildren, Aubrey Caroline and Lauren Elizabeth
Dog: Nola, Springer Spaniel

Education

PhD, 1983, Public Health, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC. Dissertation: Quantitative assessment of the interactions and activities of combinations of antimalarials in continuous culture of *Plasmodium falciparum*.

Wellcome Scholar, Earned BG Greenberg Award for Excellence in Doctoral Research
Mentors: NF Weatherly (School of Public Health), RE Desjardins (Burroughs Wellcome) and JH Bowdre (School of Medicine)

Distinguished Alumni Award, UNC, 2013

BS, MS, College of Agriculture and Biological Sciences, Clemson University, Clemson, SC

MS Thesis: Studies on the development of *Coccidia* in cell culture.
Mentors: Don Turk & John Bond (Clemson) and J. Solis (Merck)

Professional Certification & Recognition

Fellow, American Society of Tropical Medicine and Hygiene, Inaugural Class of 2011-

Fellow, American Academy of Microbiology, 1992-

Diplomate in Medical and Public Health, American Board of Medical Microbiology (ABMM), 1995. Certificate No. 872 with recertification until 2016.

Experience:

July 2007- Professor, Global Health Infectious Disease Research (GHIDR) Program
Associate Dean for Research, College of Public Health, University of South Florida (USF), Tampa, Florida. Develop strategic plans for enhancing research productivity within the College while facilitating collaboration with other colleges and programs within USF Health and the University at large. Advise the College's Research Committee and implement comprehensive strategies for research and Innovation.

Director, Center for Biological Defense (CBD)

Joint Appointment: Professor, College of Medicine, Department of Internal Medicine, Signature Interdisciplinary Program in Allergy, Immunology and Infectious Disease

Affiliations: USF Center for Drug Discovery and Innovation (CDDI), Advisory Board, 2011-
Member, Florida Public Health and Medical Preparedness Strategic Planning Oversight Team (SPOT), 2009-
Member, Florida H1N1 Guidance Analysis Group, 2009

Curriculum Vitae, Wil Milhous, 2014

- Member, Southeast Regional Center of Excellence for Emerging Infections and Biodefense (SERCEB)
- Member, Southeastern Center for Emerging Biologic Threats (SECEBT)
- Member, UNDP/UNICEF/World Bank/WHO/ Special Programme in Research and Training in Tropical Diseases (TDR) "Think Tank," Setting Priorities for Research on Infectious Diseases of Poverty.
- Fellow, USF Patel Center for Global Solutions, 2009-
- Fellow, The Florida Prevention Research Center, 2008-
- Student Infectious Disease Society, Faculty Advisor, 2008-
- Mentor, USF Health Leadership Institute, 2008-
- Member, USF Technology Development Taskforce, 2008-
- Member, National Academy of Inventors, 2010-
- Member, USF Postdoctoral Scholars Advisory Group, 2010-
- Member, Office of Research and Innovation Proposal Development Enhancement Task Force, 2009-
- Member, USF Confucius Institute Oversight Committee, 2009-
- Member, USF National Awards Resource Faculty Group, 2009-
- Member, USF Health Pharmaceutical Industry Relations Committee, 2008-
- Member USF Fulbright Scholar Reviewer Committee, 2010
- BA Research Grant Applicants
- Graduate Research Grant Applicants
- English Teaching Assistantships Applicants
- 2002-2007 Research Coordinator, Department of Defense Military Infectious Disease Research Program (midrp.org). Plan and direct research training, basic and translational research, patient diagnosis and clinical trials in a multidisciplinary program to develop new therapies for the prevention and treatment of tropical emerging diseases with special emphasis in malaria. Integrate and coordinate all aspects of research and development including management of technology, process, budget, personnel, integrated product development teams and interface with human use and institutional review boards, Food and Drug Administration, collaborating agencies and global co-development partners. Write and implement strategic plans to balance research portfolios with global marketing analysis and unmet medical needs. Chief Scientific Officer for Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD, and for Army (Bangkok, Brisbane, Nairobi) and Navy (Cairo, Jakarta, Lima) overseas research labs.
- 1999-2002 Infectious Disease Microbiology Consultant to the Surgeon General of the Army. Provided microbiological expertise, career management and graduate medical education opportunities for globally assigned commissioned officers in clinical or research disciplines of medical microbiology. Assisted in coordinating regional DoD medical centers with Laboratory Response Network (LRN) through local, state and CDC health authorities during 9/11.
- 2002-2003 Laboratory Director (College of American Pathology Approved) with principle responsibilities for diagnosis of Leishmaniasis.
- 1990-2007 Associate Professor, Department of Preventive Medicine & Biometrics with joint teaching appointments in Clinical Pharmacology and Microbiology & Immunology, Uniformed Services University, Bethesda, MD.
- 1997-2002 Director for Experimental Therapeutics, Walter Reed Army Institute of Research, Silver Spring, MD. Manage basic research efforts of Parasitology, Biology, Pharmacology, Medicinal Chemistry and Chemical Information with a total staff of

Curriculum Vitae, Wil Milhous, 2014

- 101 (10 MDs, 39 PhDs) and budget of \$14 million annual budget including \$2.2 million extramural contract program.
- 1995-1997 Deputy Director for Experimental Therapeutics, WRAIR
- 1992-1995 Director, USA Medical Research Unit-Brazil (USAMRU-B), Special Foreign Activity, Walter Reed Army Institute of Research. Direct, support and perform basic and applied research, clinical trials and patient diagnosis in a multi-disciplinary program to develop new diagnostics and drug and vaccine candidates for emerging diseases. Negotiated international health treaty entitled "*Implementing Arrangement, Relating to Health, of the Agreement Relating to Cooperation in Science and Technology Between the Government of the Federative Republic of Brazil and the Government of the United States of America, 1995.*"
- 1990-1992 Department Chair, Division of Experimental Therapeutics, Walter Reed Army Institute of Research. Direct, support and perform basic and translational research. Program and research contract manager for basic and applied research and pre-clinical efficacy testing at laboratories in the United States, India, Thailand, Panama and the United Kingdom. Member or Chair, WRAIR Human Use/Scientific Review Protocol Committees for vaccine and drug protocols.
- 1987-1990 Integrated Research Team Leader, Division of Experimental Therapeutics, WRAIR. Link basic and translational research in drug discovery and design to lead optimization.
- 1983-1987 Chief, Malaria Research Lab, Division of Experimental Therapeutics, in support of basic research in drug discovery and drug resistance.
- 1980-1983 Graduate Research Assistant (Burroughs Wellcome Scholar) School of Public Health, University of North Carolina, Chapel Hill, N.C. Teaching assistant in medical mycology & medical parasitology at UNC.

Pre-Doctoral Public Health Experience

- Specialist in Public Health & Medical Lab Microbiology, ASM Certificate No. 1250 and American Society for Clinical Pathology. ASCP Certificate No. S2909 recertification thru 2016.
- Clinical Microbiologist, Chief, Microbiology and Parasitology, Department of Pathology Womack Army Hospital (500 beds), Ft. Bragg, NC, 1975-1980
- Clinical Laboratory Officer, and Chief, Microbiology and Immunology, Department of Pathology, US Army Hospital (300 beds) Ft. Polk, LA, 1973-1975

Post Graduate Training

- National Institutes of Health, Bethesda, MD
Fellows Training Rotation in Medical Microbiology, 1990
- Duke University Medical Center, Durham, NC, 1981
Medical Mycology
Medical Immunology
- Centers for Disease Control, Laboratory Certificate Programs, Atlanta, GA
Clinical Microbiology in Control of Nosocomial Infections
Dark field Microscopy of *Treponema pallidum*
Microbiology of the Hospital Environment
Molecular Epidemiology
Laboratory Methods in Intestinal Protozoa
Laboratory Methods in Medical Mycobacteriology
Laboratory Methods in Anaerobic Bacteriology
Laboratory Methods for Diagnosis of Gonorrhea

Curriculum Vitae, Wil Milhous, 2014

Laboratory Methods for Detection of Legionnaires Disease Agent
Laboratory Methods in Special Medical Microbiology
University of North Carolina, Chapel Hill, NC, 1977-1979 (Part-time Off-Campus MPH Program)
33 Graduate Credits in Epidemiology, Biostatistics, Environmental Science,
Grantsmanship, Health Administration, Program & Budgeting, Health Structure, Health
Policy & Law.(1980-1983).
Good Clinical Practices/Human Use
Human Research Curriculum, Collaborative Institutional Training Initiative (CITI), 2009
FDA Critical Path Initiative (CPI), 2008
FDA-Regulated Electronic Documents (FRED), 2007
Principles of Clinical Data Management (CDM), 2006
USA Medical Research & Materiel Command, Regulatory Affairs Investigator Training,
2004
National Institutes of Allergy and Infectious Disease, 2003
University of Wisconsin School of Pharmacy, 1995
Pharmaceutical Education & Research Institute
Project Management in the Research-Based Pharmaceutical Industry, 1996
Department of Defense
Command & General Staff College
AMEDD Officer Basic & Advanced Courses
Management of Chemical and Biological Casualties
Medical Acquisitions, 2002

Honors and Awards

USF Research Achievement Award, 2013
Harriet Hylton Barr Distinguished Alumni Award, 2013, Gillings School of Global Public Health
for commitment and service to public health through achievements in leadership,
innovation, experimentation and collaboration within the profession, impact within the
nominee's practice arena and outstanding service beyond the requirements of the
nominee's employment.
Joseph Augustin LePrince Medal, 2009, American Society of Tropical Medicine & Hygiene, in
recognition of outstanding work in the field of malariology.
Faculty Fellows Program Award, Patel Center for Global Solutions, USF, 2007
Pharmaceutical Achievement Award for Social Responsibility, presented to the Institute for
OneWorld Health, 2005, Advisory Board Member.
USA Research & Development Award for Small Business Innovative Research, 2000
USA Research & Development Achievement Award, 2000, for assisting in the development and
FDA approval of Glaxo SmithKline Malarone.
Bailey K. Ashford Medal, 1993, the American Society of Tropical Medicine and Hygiene for
distinguished work in tropical medicine for basic research contributions in drug discovery
and drug resistance.
The Gorgas Medal, 1988, Society of Federal Health Agencies for notable contributions in
prevention medicine through methods development and initiation and establishment of
the DoD Science and Technology Objective for Global Surveillance and Detection of
Drug Resistant Malaria.
USA Research & Development Achievement Award, 1988, for discovery of resistance
modulator drugs.
BG Greenberg Award for Public Health Research, 1984, UNC School of Public Health, methods
development in malaria susceptibility testing for antifolate drug combinations.
Finalist, MEPHA International Prize in Malaria Chemotherapy, 1994
Directors Award, Walter Reed Army Institute of Research, 1992

Honorary Societies

Delta Omega (Honorary National Public Health)
Gamma Sigma Delta (Honorary Agriculture)
Sigma Xi (The Scientific Research Society)
Mu Beta Psi (Honorary Music)

Military Awards

The USA Legion of Merit, 2002
USA Medical Department Medallion, 2002
Order of Military Medical Merit, 1992
"A" Proficiency Designator Award, Office of the Surgeon General, 1989
USA Meritorious Service Medals (4) 1997, 1995, 1991, 1979
The Expert Field Medical Badge, 1984
USA Achievement Medal, 1986
USA Commendation Medal, 1976
Armed Forces Reserve Medal, 1983
Army Service Ribbon
Overseas Service Ribbon
National Defense Service Medals (3)

Teaching Experience

PHC 7931 (CRN27613) and CHM 6938 (CRN 27612) Drug Discovery for Tropical Diseases
Spring Semester 2012
PHC7931 Advanced Interdisciplinary Seminar in Public Health (Summer 2010, 2011, 2012)
PHC7931 Global Health Infectious Diseases Seminar (Fall 2007-)
PHC6510 Global Emerging Infectious Diseases (Fall 2008-)
PHC6945 Global Health Field Experience (Fall 2000-)
PHC6115 Global Health Principles & Contemporary Issues (Fall 2008-)
PHC7931 Global Health Drug Discovery for Tropical Diseases (Spring 2009-)
PHC6934 Infectious Disease Epidemiology-Vaccines (Summer 2009)
CHE6936 Medicinal Chemistry Colloquium (Spring 2009-)

2007-2008 Rollins School of Public Health, Emory University, Atlanta, Georgia
GH 590R- Malaria: A Global Public Health Concern

1985-2007 WRAIR Formal accredited training programs
Preventive Medicine Residency
Laboratory Animal Medicine Residency
Clinical Pharmacology Fellowship

1985-2007 WRAIR Postdoctoral programs
Medical Research Fellowship
National Research Council Post-Doctoral Associateships

1985-2007 WRAIR Community Outreach Programs
Gains in the Education of Mathematics and Science, ages 13-18
Science and Engineering Apprenticeship Program-SEAP for high school students
College Student Leadership Program-CQL for college students
Science for Elementary Teachers Program for teachers of grades 3 through 6

1990-2007 Adjunct Associate Professor (Assistant 1984-1990) Uniformed Services
University of the Health Sciences, Bethesda, MD.

Curriculum Vitae, Wil Milhous, 2014

- Medical Microbiology/Parasitology for Medical Students (16 semesters)
Chemotherapy/Pharmacology for MPH/PhD Students (5 semesters)
Scientific Mentor, Clinical Pharmacology Fellowship Training Program
- 1993-1996 Visiting Scientist, Foundation of the Institute of Oswaldo Cruz, Rio de Janeiro
- 1989-present Adjunct Assistant Professor, University of North Carolina, Department of Parasitology & Laboratory Practice (Epidemiology), Gillings School of Public Health
- 1991-1992 Adjunct Assistant Professor, Bowling Green State University, Bowling Green, OH, Allied Health Research Advisor
- 1991-2007 Visiting Professor, Tropical Infectious Diseases, Central Military Hospital, Bogotá, Columbia
- 1984-1992 Walter Reed Army Institute of Research, WRAIR
Postgraduate Course in Tropical Medicine
- 1988-1991 Montgomery College, Takoma Park, MD (evenings part time)
Microbiology 203 for Nursing & Medical Technology Students (3 semesters)
- 1982 University of North Carolina, Gillings School of Global Public Health, Medical Mycology Laboratory
- 1981-1982 UNC and Duke Schools of Medicine, Medical Parasitology Laboratory (2 semesters)

Postdoctoral Fellows/Research Training

University of South Florida

Yulia Serebrennikova, PhD, 2009-10

Fogarty Foundation

Christian Happi, PhD, 2005-7

Infectious Disease Fellows

Cindy Tamminga, MD, MPH 2006-7

Peter J. Weina, MD, PhD, 2001-2

Clinical Pharmacology Fellows

Colin Ohrt, MD, MPH 1995-1997

Mike Riel, MD 2000-2

Kevin Canard, MD, 2004-6

David Sanders, MD, 2005-7

National Research Council Postdoctoral Fellows

Malcolm Gardner, PhD, 1991-3

Russel Coleman, PhD, 1992-4

Dibyendu De, PhD, 1991-13

David Wesche, MD, PhD, 1988-90

J. Guan, PhD 2002-2005

World Health Organization Postdoctoral Fellows

Quigui Li, 1995-1997

Mariano Zalis, PhD, 1994-1997

Xiuhong Li, MD, 1992-1994

Jun Li, MD, 1987-89

Advisor MPH/MSPH/PhD Students

Nicanor Obaldia, DSc, 2013. Harvard University. On the diversity of Panamanian malaria isolates and the characterization of Plasmodium vivax transmission stages. Dissertation Committee.

Curriculum Vitae, Wil Milhous, 2014

- Stephen Casey Harbison PhD 2013. Evaluation of Pulmonary Risks Associated with Selected Occupations, Chair. Dissertation Committee
- Samantha Aylor, MSPH, 2013. Effect of Drug Resistance on Plasmodium falciparum Transmission and Gametocyte Development. Thesis Committee.
- Jenifer White, PhD, 2013, Development of a Novel Method for Thresholds of Toxicological Concern (TTCs) for Vaccine Constituents. Chair. Dissertation Committee
- Amanda Rutter, MPH 2013. Advisor, Field Experience: Internship in Florida Hospital Infections Control Department. Special Project: Impact of personal protective equipment use and hand hygiene compliance on healthcare associated infections in an acute care facility.
- Dzidzo Regina Yirenya-Tawiah, PhD, 2010. Thesis Advisor. Visiting Doctoral Student, University of Ghana. The Epidemiology of Genital Schistosomiasis Among Women of Reproductive Age in the Volta Basin of Ghana: Co-Infection with Sexually Transmitted Infections and HIV.
- Christen L. Mayer, MPH Special Project Advisor (Dual Degree in Epidemiology and Global Communicable Diseases), 2010. Acinetobacter baumannii: a review of international outbreaks.
- Janus Patel, MPH 2010, Special Project, Interpretation of the UV-Visible spectra of lethal human falciparum malaria: science and innovation forging global public health solutions.
- Cosby, Michael, MPH, 2010, Sponsor, Field Experience Cairo, Egypt.
- Jane Barkan, MSPH, 2012, Thesis Committee, Wastewater treatment plants and facilities in elimination of *Giardia* cysts and *Cryptosporidium* oocysts
- Lindsay Morton, USF Library Scholarship & Special Project Advisor
- Olabode Oyekoya, MD, MPH, 2010 Field Experience, HIV services, Drug Abuse Comprehensive Coordinating Office, 2009
- Sydnor Richkind, MPH, 2009, Field Experience, An Evaluation of the Evidence-based Merits of Adolescent Health Services in Saint Lucia. Special Project: Adolescent health status and care in St. Lucia & options for improvement
- Michael Klingshirm, MPH. Incidence of Clostridium difficile Infections Among 2009 Influenza A/H1N1 Positive Patients from April to December 2009 by Michael Klingshirm, BS
- Meredith Tennouri, MPH, 2009, Sponsor, Field Experience at WHO-TDR: What is the current funding environment of health research of neglected tropical diseases?
- Darcy Webber, MPH, 2009, Special Project, The Role of the student in Interdisciplinary Research and the Critical Path, 2009, Food & Drug Administration
- Jessica Schilke. MPH 2009, Artemisinin-Based Combination Therapy (ACT) Drug Resistance Trends in Plasmodium falciparum Isolates in Southeast Asia
- Lucio Malvisi, MSPH, 2009, MS Thesis: Functional Characterization of Cytochrome b5 Reductase and its Electron Acceptor Cytochrome b5 in *Plasmodium falciparum*
- Nadia Need, MPH, 2008, Field Experience, The South Texas Environmental Education and Research
- Julia C. Mead, MPH, 2007. Funding Drugs Used to Combat Global Health Diseases.(Columbia University Mailman School of Public Health, Thesis Advisor)
- Adaymee Cofresi, MS, 2007. Increasing Parasitemia Modulates In Vitro Concentration Response to Artemisinin Drugs: Can Parasite Burden Alter Treatment Outcomes in Severe and Complicated Malaria? (George Washington University, Washington, DC. Thesis Advisor).
- Cindy Tamminga, MD, MPH, 2007, *Plasmodium falciparum* infection among US Marines deployed to Liberia: comparison of mefloquine resistance patterns to archived Liberia isolates and previous studies (Uniformed Services University, Bethesda, MD),.
- Glorimar Alvarado, MS, 2003. Investigation of the antimalarial activity of *Cissampelos pareira* L. (Menispermaceae) (University of Puerto Rico, Committee Member)

Curriculum Vitae, Wil Milhous, 2014

Lyndale Emerson, PhD, 2001. Genetic and Transcriptional Profile Analyses in *Saccharomyces cerevisiae* Reveal Role for Quinoline-Ring Antimalarial Drugs in Iron Uptake. (Harvard School of Public Health Dissertation Examination Committee)
Michael Libby, MS, 1991. Erythrocyte Age and Dose Response. (Bowling Green University, Advisor for Blood Bank Fellowship)
Sheila Peel, PhD, 1991. Mefloquine Resistance in Multidrug Resistant *Plasmodium falciparum* *in vitro*. (University of North Carolina, Committee Member)

Undergraduate Honors Student Thesis Advisor at the University of South Florida

Lakraj, Amanda, BS, 2008, G6PD Deficiency as a Pharmacogenomic Health Disparity
Kim Dau, BS, 2009, A Handbook to Good Hygiene
Violetta Yevstigneyeva, 2010, The Development of Axenic Amastigote Culture of *L. donovani* to Improve the First Line Drug Screening for Visceral Leishmaniasis Research.
Danielle Wales, 2010, The Role of Faith-based Organizations in the Implementation Science of Malaria Prevention and Treatment in East Africa.
Sherlin Paul, 2010, Causes of Inequalities in Infection Rates Among the Poor
Aimal Nikamal, 2010, Unequal Health

USF Search Committee Membership

Member, Associate Vice President for Research, 2009
Member, Dean, School of Pharmacy, 2009
Member, Dean, Graduate School and Vice President for Research & Innovation, 2009
Chair, Associate Professor, Global Health Communicable Diseases Track, 2009
Chair, Associate Professor, Global Health Humanitarian Assistance Track, 2009
Chair, Marrell Endowed Chair in Community and Family Health, 2008

Member, Professional Education and Training Committee for Graduate Medical Education

Walter Reed Army Institute of Research (1999-2003):
Preventive Medicine Residency Program
Clinical Pharmacology Fellowship
Laboratory Animal Medicine Residency Program
Military Medicine Fellowship Program

Ongoing Research Support

Countermeasures to Emerging Biological Threats, Milhous, PI
USF 64151014 12/16/2008 - 11/30/2012 DoD-RDECOM \$2,293,177 Total
USF 64151021 01/25/2011 - 07/24/2014 DoD-RDECOM \$1,830,927 Total
USF 64151022 09/29/2010 - 05/31/2013 DoD-RDECOM \$1,403,353 Total
Dual-use disease surveillance for bioterrorism and other public health emergencies, the design, development, and evaluation of educational and training materials on biodefense for first responders, and management of research on a broad spectrum of technologies with applications to rapid recognition and response to potential bioterrorist events.

Previously Funded

USF-UF New Florida Cluster Award for Vector Borne Diseases. Optimizing Detection, Prevention and Treatment of Vector-Borne Diseases, Milhous (USF Co-PI with Jim Baker, PhD 01/01/11-06/30-2012)

Curriculum Vitae, Wil Milhous, 2014

Florida I4 Corridor Program Milhous (PI) 1/1/9/-6/30/10 NCE
Photonics Methods for Diagnosis of Malaria, Claro Scientific. Evaluates novel point of care tests for Diagnosis of Malaria and Anemia

DoD RMS # 07213002 Milhous (Co-PI) 9/12/09-9/11/11
Development of safer drugs for malaria and leishmaniasis. DoD RMS # 07213002. PR: W23RYX7226N601 9/12/09-9/11/10

Scientific Advisory Committee: USF/Moffitt Transdisciplinary Center to Address Cancer Health Disparities NIH 1P20MD003375-01. 5/8/09 – 12/31/13.

Advisory Board: D43TW007990-01 IPF: 513807 Program in Adolescent HIV/AIDS Research Training (PAHRT) PI: Emmanuel, Patricia J. 09/11/2007 – 12/30/2012

DoD-RDECOM Milhous (PI) 9/26/07-9/25/11
Florida Consortium for Emerging Threats (FBRC). Consortium for Universities in Florida for discovery and development of interventions for emerging diseases.
6415101261 Florida Atlantic University (FAU). Identification of Genes Essential for Growth & Prediction of Antimicrobial Targets in Yersinia Pestis
6415101262 Florida Atlantic University (FAU) Development of Anti-Microbial Nanoparticles Composed of a Magnetic Core & Covered w/Photocatalytic TiO₂
6415101263 University of Central Florida (UCF) Tunable Optical Sensors for Microarray Technology
6415101264 University of Florida (UF) Proteolytic Phenotype & Virulence of the Mycoplasma Mycoides
6415101265 University of Central Florida (UCF) Development of Customer Programmable Microfluidic System for Biosensors including the "Taste Chip"
6415101266 Florida Gulf Coast University (FGCU) New Biocides & Decontamination Agents for Bio-Defense
6415101267 Florida Gulf Coast University (FGUC) Rapid Detection Systems to Monitor Viral Pathogen Viability
6415101268 University of West Florida (UWF) Diagnostics for Intentionally Released Human Pathogen in Surface & Drinking Waters
6415101269 University of Florida (UF) A Strategy for Elimination of Human Pathogen Contaminated Raw Produce from the Food Supply
6415101270 University of Florida (UF) Development of Transcriptome Analyses of Category B Encephalitis

Co-PI: Drug Resistance Networks in Kenya, Peru, Thailand, Ghana. DoD-GEIS GM0056_07WR \$800K, 2002-08.

Research Coordinator, Senior Advisor, Military Infectious Disease Research Program, \$48 Million, 2002-2007

Senior Advisor and Co-PI: Optimization of Radical Curative and Causal Prophylactic Drugs, Medicines for Malaria Venture, Geneva, Switzerland; \$3 Million, 2006-7

Senior Advisor: Development of Third Generation Macrolides, Pliva Pharmaceutical, Zagreb, Croatia, and Medicines for Malaria Venture, Geneva, Switzerland. 2006-7.

Senior Advisor: Lead Optimization and Pre-Clinical Studies of Imidazolidinedione Derivatives, Peer Reviewed Medical Research Program (PRMRP), \$3 Million, 2005-2007

Senior Advisor: NIAID Challenge Grant: Joint Ventures in Biomedicine and Biotechnology 1RC AI48874-01; WRAIR-SmithKline Beecham: Tafenoquine, new drug for malaria treatment and control; \$7.3 million, 2001-2006

Curriculum Vitae, Wil Milhous, 2014

Senior Advisor: NIAID Challenge Grant: Joint Ventures in Biomedicine and Biotechnology 1RC AI48859-01. WRAIR-Pfizer: Azithromycin Combination Treatments; \$600K, 2001-2006.
Consultant: Harvard School of Public Health
Fogarty International Research Training Grant. "Training in Malaria Pathogenesis and Diversity in Africa" D43 TW001503 4/1/07 - 3/31/2010 \$133,950.
Fogarty International Research Collaboration Award (FIRCA). "Molecular 1/15/2004-12/31/2006 (extended through 12/31/07).
Co-PI: Artesunate for Severe and Complicated Malaria, Medicines for Malaria Venture, Geneva, Switzerland; 2003 (\$800K), 2004 (\$620K)
Associate Program Leader: NIAID/Fogarty International Cooperative Biodiversity Group (ICBG) Program for West and Central Africa TW00327, \$3 million, 2000-2005
Principal Investigator (PI): World Health Organization, Special Program for Research and Training in Tropical Diseases (TDR), Chemotherapy of Malaria (CHEMAL), 1984-87 (\$101K), 1988-91(\$140K), 1991-93(\$230K), 1994-(\$82K), Co-PI 1996-2002 (\$382K)
PI: Human metabolism of arteether, WHO TDR CHEMAL 1997-2000 (\$178K).
PI: Analysis of arteether and related drugs in clinical samples WHO TDR CHEMAL, 1997-2001 (\$320K).
Co-PI: Harvard University School of Public Health; Surveillance & Detection of Drug Resistant Malaria, NIAID International Center for Tropical Disease Research (ICIDR), 1995-2000.
Co-PI: Optimization of Sequencing Strategies for the Malaria Genome, Joint NIAID and DOD Sponsored, 1997-2002 (\$3 million).
PI: WRAIR Independent Research Awards, 1993-94 (\$68K), Co-PI 1986-92 (\$220K).
Sponsor: Rockefeller Foundation Biotechnology Fellowship, 1990-1992 (\$60K).
Sponsor: Molecular Basis of Resistance in Falciparum Malaria. WHO TDR, 1994-6 (\$50K).
Co-PI: Characterization of West African Isolates of Falciparum Malaria WHO TDR, 1986-92 (\$240K).
Co-PI: Drug Combinations in Chemotherapy, WHO TDR CHEMAL, 1992-95(\$200K).
Co-PI: Pharmacokinetics and metabolism of arteether. WHO TDR CHEMAL, 1988-92 (\$130K).
Co-PI: Sporontocidal Properties of WR238605, WHO TDR CHEMAL, 1989-92 (\$120K).

Editorial Positions and Appointments

Editor

Antimicrobial Agents and Chemotherapy, 2012-2017

Editorial Board

Journal of Clinical Microbiology, 2010-

Antimicrobial Agents and Chemotherapy, 2009-2012

Tropical Medicine, 2008-

Experimental Parasitology, 2005-

Technology and Innovation, 2010- (Editorial Advisory Board)

Recent Patents on Anti-Infective Drug Discovery, 2006-2010

Memorias do Instituto Oswaldo Cruz, 1993-1996; 2010-

Journal of Military Medical Laboratory Science, 1989-1992

Reviewer

American Journal of Tropical Medicine and Hygiene

Antimicrobial Agents & Chemotherapy

Biochemical Pharmacology

Expert Review of Anti-Infective Therapy

Journal of Clinical Microbiology

Journal of Infectious Disease

Journal of Medicinal Chemistry

Journal of Parasitology

Molecular and Biochemical Parasitology

Nature

Nature Reviews

New England Journal of Medicine

Proceeding, National Academy of Sciences

PLoS Medicine

Curriculum Vitae, Wil Milhous, 2014

Journal of Natural Products
Protein and Peptide Letters

Science

Committee Assignments and Administrative Experience

- 2007-2013 Expert Scientific Advisory Committee (ESAC), Medicines for Malaria Venture (MMV), Geneva, Switzerland
- 2010- Reviewer, Health Resources and Services Administration (HRSA's) Division of Independent Review (DIR).
- 2013- Chair, Peer Reviewed Medical Research Program (PRMRP) Clinical Trials Award Panel, Congressionally Directed Medical Research Programs (CDMRP); Member, PRMRP-CDMRP Discovery Award Infectious Diseases (Dis-ID)
- 2001- Reviewer, National Institutes of Allergy and Infectious Diseases (NIAID) Infectious Diseases and Microbiology
Drug Discovery & Mechanisms of Antimicrobial Resistance ZRG1 DDR 01, 2001, 2011
Special Emphasis Panels/Scientific Review Group (SRG) 2006/05 ZRG1 IDM-M (02), SRG 2006/05 ZAI1-ACM- C1, SRG 2005/04 ZRG1 IDM-M (03)
Roadmap Transformative R01 Program (R01).RFA-RM-08-029
American Recovery and Reinvestment Act of 2009. RFA-OD-09-003
Congressionally Mandated Peer Reviewed Research Program
Chemotherapy of Leishmaniasis, September 2008
Wound Healing, Sepsis Chemotherapy, January 2009
- 2010- Member, UNDP/UNICEF/World Bank/WHO/ Special Programme in Research and Training in Tropical Disease "Think Tank," Setting Priorities for Research on Infectious Diseases of Poverty.
- 2007- Stakeholder, Ten Years Strategy & Vision, Strategic and Discovery Research (SDR) UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases (TDR), World Health Organization, Geneva, Switzerland
- 2005- Malaria Global R&D Alliance: Advisory Board Member and expert in malaria and global tracking. Guided the development of survey instrument and reviewed final report for the following funding recommendations from the Bill and Melinda Gates Foundation:
\$107.6 million to the PATH Malaria Vaccine Initiative (MVI) to work with GlaxoSmithKline Biologicals and African investigators to complete testing and apply for licensure of the most advanced malaria vaccine candidate
\$100 million to the Medicines for Malaria Venture (MMV) to work with public and private sector partners to accelerate the development of several promising new drugs through regulatory approval
\$50.7 million to the Innovative Vector Control Consortium (IVCC), led by the Liverpool School of Tropical Medicine, to fast-track development of improved insecticides and other mosquito control methods
- 2005-2007 Advisory Committee, Novel Macrolides, Pliva Research Institute, Zagreb, Croatia
- 2002-2004 National Institutes of Allergy and Infectious Diseases (NIAID). Summits on Infectious Disease Therapeutics, DoD representative
- 2004 National Academies, Board on Global Health, July 21-22, Washington, DC. Opinion Leader for Malaria Control: A Reconsideration of the Role of DDT
- 2004 Institute of Medicine, Research and Development for new Antimalarial Drugs In: Saving Lives, Buying Time: Economics of Malaria Drugs in an Age of Resistance, pages 301-211, 2004

Curriculum Vitae, Wil Milhous, 2014

- 2003-present Advisory Board, National Center for Natural Products Research, University of Mississippi, School of Pharmacy
- 2003-present Key Opinion Leader (KOL), Glaxo SmithKline Pharmaceuticals, Immune Status and Causality of 8-Aminoquinolines
- 2000-2006 Expert Advisory Panel , US Pharmacopoeia
- 1998-present Chair (2006) International Board of Directors, the Malaria Foundation Int'l
- 2000-02 Board of Advisors, American Type Culture Collection (ATCC)
- 1999-present Tafenoquine Steering Committee and Global Advisory Panel, Glaxo SmithKline Pharmaceuticals
- 1999-2007 Advisory Committee, Food and Drug Administration, FDA-CBER, Biological Therapeutics
- 2001-2007 Advisory Committee, Institute for One World Health (IOWH), San Francisco, CA,
- 1997-2002 Steering Committee, Drug Discovery Research (DDR) for Malaria, Tuberculosis, Leishmania, and African Trypanosomiasis, Chagas Disease, Filariasis, Tropical Disease Research (TDR) World Health Organization
- 2002-2005 Screeners Committee, WHO-TDR
- 1998-2004 Associate Program Leader: NIAID/Fogarty International Cooperative Biodiversity Group (ICBG) Program for West and Central Africa
- 1987-2007 Senior Research Advisor, National Research Council
- 1998- Organizer or Participant, Rockefeller Foundation Interdisciplinary, Intercultural Working Groups, Bellagio, Italy
- Lactate Dehydrogenase in Malaria, 1994
- Public Health Applications of Improved Diagnostics, 2001
- Genomics in Discovery of Drugs for Tropical Diseases, 2005
- 1997- Multilateral Initiative on Malaria (MIM) Working Groups: Dakar, Senegal; The Hague, Netherlands; Durban, South Africa: Arusha, Tanzania; Stockholm, Sweden; Yaoundé, Cameroon. Participants: Pasteur Institute; Commission of the European Communities; the Wellcome Trust; Medical Research Council; World Health Organization; Centers for Disease Control and Prevention; Netherlands Organization for Scientific Research
- 1990-1992 National Academy of Sciences, Institute of Medicine, Washington, DC. Member, United States Committee on Malaria Prevention and Control.
- 1987- Member & Co-Founder, US Interagency (WRAIR, Department of State, Peace Corps, CDC & FDA) Chemoprophylaxis Working Group
- 1990-1992 Member, Preventive Medicine Problem Definition & Assessment Team, Operation Desert Storm
- 1987- National Institutes Allergy and Infectious Disease, Study Section Special Member Tropical Medicine & Parasitology 1987, 1989, 2004
- Opportunistic Infections, 1997
- 1985-1992 Member, Biotechnology/Parasitology Study Panel, Program for Science & Technology Cooperation, Agency for International Development, Chairman, 1987

Research Compliance and Regulatory Affairs for Investigational New Drug/New Drug Applications (*Discussion or pre-clinical efficacy leader for FDA-Special Pathogens type A,B,C meetings)

WR= Walter Reed Number

WR006026 (GSK-Sitamoqiune) Program Director and Co-PI, Phase II Clinical Trials in Brazil

WR100553 (Doxycycline-Pfizer-Vibramycin) Pre-Clinical Efficacy, Support Phase II and Phase III in Thailand

Curriculum Vitae, Wil Milhous, 2014

WR149240 (Mefloquine-HLR-Lariam) Pre-Clinical Efficacy/Resistance/Support Clinical Trials, Post Marketing Surveillance and Adverse Events
WR171669 (Halofantrine-GSK-Halfan) Pre-Clinical Efficacy/Resistance/Support Clinical Trials
*WR238605 (GSK-Tafenoquine) Pre-Clinical Efficacy and Supporting Phase I, Program Director Phase II, for Indonesia, East Timor, and Kenya
WR245567 (Sulfadoxine/Pyrimethamine-Roche-Fansidar) Post Marketing Surveillance, Resistance, Adverse Events.
*WR255131 (Arteether-Artecef-Artemotil) PI, Pre-Clinical Efficacy and Phase III PK Analysis
WR255663 (Artelinic Acid) Co-Inventor, Pre-Clinical Efficacy, FDA Consultations on Neurotoxicity, Program Director
*WR256343 (IND 64769), Intravenous Artesunate for Severe Malaria, Pre-Clinical Efficacy Integrated Product Development Team MMWR August 3, 2007 / 56(30);769-770
WR279277 (Pfizer-Azithromycin-Zithromax combinations) Co-Inventor, Pre-Clinical Efficacy, Program Director for Phase III in Indonesia, Peru and Thailand.
WR279396 Topical Antileishmanial, Program Director
WR279825/WR003091 (Atovaquone/Proguanil GSK-Malarone) Pre-Clinical Efficacy/Resistance and Co-PI for Phase III Clinical Trial in Brazil
Malaria Rapid Diagnostic Device (MRDD), Lead Optimization, Platform Selection, Support Clinical Trials for 510K Application. MMWR July 13, 2007 / 56(27);686

Membership in Societies:

American Public Health Association, 1979-1982; 2007-
Domain for Strategic Analysis and Evaluation, Core Workgroup, Global Health Core Competency Development Project, 2010-2012
Liaison to Association of Schools of Public Health (ASPH), American Society of Tropical Medicine and Hygiene, 2010-
Discussion Leader APHA/ASPH Associate Deans for Research
Organization & Composition of Research Committees, Washington, DC & University of Maryland, October, 2011
Conduct of International Research, Portland, Oregon, June 2012
Research Incentives for Public Health Faculty, San Francisco, October 2012

American Society of Tropical Medicine and Hygiene, 1981-present

Round Table Host: Global Health Speed Networking Session, 2013
Founding Co-Chair, ASTMH Committee on Global Health, 2010-
Co-Chair and Organizer, Symposium for Global Health Competencies, 2011
Co-Organizer and Presenter: Intravenous Artesunate for the Treatment of Severe Malaria - Past, Present and Future, 2010
Co-Organizer and Presenter: Setting Priorities for Research on Infectious Diseases of Poverty, 2010
Co-Organizer and Presenter: Global Health Second Annual Rapid Diagnostics in Low Resource Settings: Why Bad Things Happen to Good Interventions, 2010
Chairman and Co-Organizer, Symposium: Strategies for Water and Sanitation A Multidisciplinary Approach for Sustainable Communities, 2009
Co-Organizer, Symposium Keynote: Towards non-hemolytic 8-aminoquinolines: G6PD as a Pharmacogenomic Health Disparity, 2008
Co-Organizer, Symposium Bridging Pathogenesis and Pathology in Malaria: Addressing Drug

Curriculum Vitae, Wil Milhous, 2014

Resistance and Tolerance in Malaria Parasites, 2007
Co-Organizer, Symposium on Severe Malaria & Anemia in Children, 2006
Sponsor, Honorary Member Award, Dr. John Horton, 2006
Co-Organizer, Symposium on 8-aminoquinolines, Past, Present and Future, 2005
Co-Organizer, Symposium on Parasite and Host Gene Expression in Malaria, 2005
Co-Organizer, Symposium for Surveillance of Drug Resistance Malaria, 2005
Sponsor, Honorary Member Award, Professor Karl Rieckmann, 2004
Sponsor, Austin LePrince Prize in Malariology, Dr. Craig Canfield, 2003
Organizer, Symposium on Public Private Partnerships for Infectious Disease Therapeutics, 2003
Chairman, Symposium on Drug Combinations, 2000-
Chairman, Symposium on Malarone® (Atovaquone and Proguanil), 1996
Organizer, Symposium on Methods for Diagnosis of Malaria, 1996
Co-Organizer, Symposium on Malaria Prophylaxis, 1999
Chairman, Scientific Sessions on Antimalarial Chemotherapy, 1985, 1989
Chairman, Symposium on Multidrug Resistant Falciparum Malaria, 1987
Chairman, Symposium on Artemisinin Drugs, 1990

American Society for Microbiology

Invited Symposium: Managing R&D Portfolios in Antimicrobials and Diagnostics, 2008
Invited Symposium: Careers in Microbiology; Opportunities in Government, 2002.
American Academy of Microbiology
Tellers Committee, 1998-2002
Chair, Scherago-Rubin Award Committee, 2007-10; Member 2006
American Board of Medical Microbiology, Examination and Standards Committee, 1998-Present
American Society for Clinical Pharmacology and Therapeutics, 2002-
American Society for Clinical Pathology, 2002-
International Congress of Pharmacology: Chairman, Symposium on new approaches to the treatment of malaria, 2002
Infection Disease Society of America, Invited Symposium: Private-Public Partnerships for Drug Development for Tropical Diseases, Vancouver, Canada, 2010
American Society of Pharmacognosy, Invited Symposia, 1991, 1995
Royal Society of Tropical Medicine and Hygiene, 1988-present

Grants Management, Small Business Innovative Research (SBIR) & Contracts

High-Throughput Proteomics Strategy for Detection and Identification of Biomarkers of Exposure, SBIR II, Sun BioMedical, 2005-2007
Novel Routes of Drug Administration, SBIR II, Advanced Sensor Technologies, 2005-2007
Analytical and stability Studies of Chemicals, Stanford Research International, 1995-2007.
Analytical methodology development and analysis of drugs in biological fluids, University of California at San Francisco, 1995-2007
Chemical and drug repository, McKesson Associates, Rockville, MD, 1995-2007
Drug Evaluation in Primates, Gorgas Memorial Laboratory, Panama, 1985-90; 1996-2007
Evaluation of Chemotherapeutic Agents, University of Miami, School of Medicine, 1990-1992
Malaria Chemotherapy, London School of Tropical Medicine & Hygiene, London, 1987-1990
Methods for Diagnosis of Falciparum Malaria, SBIR I & II, 1998-2001
New Drugs for Malaria and African Trypanosomiasis, USUHS, 1985-1990
Pharmacodynamics and pharmacokinetics and acute toxicology studies, Southern Research Institute, Birmingham Alabama, 1995-2002
Pre-formulation studies and formulation production, University of Iowa, Ames, Iowa, 1995-2004

Curriculum Vitae, Wil Milhous, 2014

Preparation of chemicals and bulk drugs, Starks Associates, Buffalo, NY, 1995-2005
Preparation of radio-labeled compounds, Research Triangle Institute, RTP, NC, 1995-1997
Radical curative testing in primates, AFRIMS, Bangkok, Thailand, 1984-2007
Synthesis and Screening of Antimalarial Drugs, Central Drug Research Institute,
Lucknow, India, 1985-1998 (Department of State US India Fund)

Chemotherapy Patents and Invention Disclosures

US Patent Office -15

European Patent Office-6

World Intellectual Property Organization (WIPO)-6

1. Artemisinins in the clinical and veterinary management of kinetoplastid infections II. PCT 13/999,318, February 4, 2014.
2. Artemisinins in the clinical and veterinary management of kinetoplastid infections I 8,715,751. Issued May 6, 2014.
3. Artemisinins in the clinical and veterinary management of kinetoplastid infections II. PCT 13/999,318, February 4, 2014.
4. 7,566,465. Issued 28 July, 2009. Synthetic artemisinins in the clinical and veterinary management of kinetoplastid infections.
5. 7,101,902. September 5, 2006. 2-guanidinylimidazolidinedione compounds and methods of making and using thereof. 2004038909. European 04821254. 2-2107.
6. 7,084,132. August 1, 2006. Artemisinins with improved stability and bioavailability for therapeutic drug development and application.
7. 20040019200. January 29, 2004. Mixed steroidal 1,2,4,5-tetraoxane compounds and methods of making and using thereof. Serial No. 359584, February 7, 2003.
8. 20030171424. September 11, 2003. Intravenous formulation of artelinic acid for treatment of severe and complicated malaria. Serial No. 376420, February 27, 2003.
9. 20090156687 Fab I and inhibition of apicomplexan parasites. June, 18, 2009. 2 0040137446. July 15, 2004. PCT/US01/49738 filed 12/20/2001; and U.S. Patent Application No. 10/465,527 filed 06/18/2003
10. 20040053950. March 18, 2004. Antimalarial activities and therapeutic properties of febrifugine analogues. Serial No. 600446, Filed June 20, 2003.
11. 20030032801. February 13, 2003. Chemosensitizing agents against chloroquine resistant Plasmodium falciparum and methods of making and using thereof. Serial No. 849400, May 7, 2002. PCT/US01/14574.
12. 4,791,135. December 13, 1988. Novel antimalarial dihydroartemisinin derivatives. Serial No. 087365, August 29, 1987.
13. 4,897,403. January 30, 1990. Antimalarial Compositions and Methods. Serial No. 936677, filed November 18, 1986. European No. 8900622.7
14. Synergistic Combinations of Azithromycin for Malaria Treatment, Filed May 2001
15. Prophylaxis Against Transfusion Acquired Chagas Disease, Filed June 1996
16. Treatment & Prophylaxis of Toxoplasmosis, Filed June 1997
17. Treatment & Prophylaxis of Pneumocystis Pneumonia Using 8-Aminoquinolines, Filed 1992
18. Diamine Complexes of Silver Sulfonamides in Chemotherapy. File No. 77181 Sep 5, 1985

Publications Sorted by Impact Factor

28.75 Nature 393: 801-805; 397: 219-220

- 28.64 *Lancet*. 8571: 1304-5; 9287: 1066-7
- 26.37 *Science* 327: 279-80; 242: 1301-3; 238: 1283-5; 235: 899-901; 379: 279-80
- 09.60 *PNAS* 87: 3018-22; 84: 7310-14
- 05.85 *J Inf Dis* 185: S25-S36; 180: 1282-1287; 165: 764-8; 175: 1544-7; 165:764-8.
- 05.25 *J Med Chem* 55: 1389-401; 54: 3595-605; 51:4388-91, 2261-6; 50: 6226-31, 5118-27; 99: 3790-99; 48: 6472-81, 2805-13; 45: 3331-6; 43: 3274-82, 2753-8, 1246-9, 41:4360-4; 38:5038-44.37:1256-8; 36:4264-75; 35:3023-7, 2459-67; 35:2129-34; 33:1516-8; 31:645-50; 30:2147-50.
- 04.90 *Current Drug Therapy* 2: 210-223
- 04.67 *Antimicrob Agents Chemother* 53:8888-95; 51: 2898-904; 49:3463-7; 46:2627-32; 46:2518-24; 43:598-602; 38:1392-6; 36:2761-5; 36:1538-44; 35:277-82; 33:1090-4; 27:525-30.
- 04.67 *Int J Pharmacog* 31:255-258
- 04.53 *Parasitol Today* 14: 376-377; 9: 167-168
- 04.39 *Antimicrob Agents Chemother* 53:8888-95; 51: 2898-904; 49:3463-7; 46:2627-32; 46:2518-24; 43:598-602; 38:1392-6; 36:2761-5; 36:1538-44; 35:277-82; 33:1090-4; 27:525-30.
- 04.20 *PLoS One*. 2010 Dec 9;5(12):e13275. *PLoS Negl Trop Dis*. 2008 Mar 5;2(3):e190
- 03.91 *Drug Metab Dispos* 36: 380-5
- 03.40 *Int J Parasitol* 31: 109-13.
- 03.10 *Malaria Journal* 2011 Jul 29;10:212. 5:82 doi:10.1186/1475-2875-5-82.
- 02.98 *J Chem Inf Comput Sci*. 42:1212-20; 37:124-30
- 02.98 *Cytometry A* 71:297-307.
- 02.90 *Mol Biochem Parasitol* 57: 151-60
- 02.60 *Bioorg Med Chem* 22: 786-78919:1692-701; 13: 699-704; 11: 2761-8.
- 02.55 *J Nat Prod* 65: 614-5; 56: 1954-61; 47: 715-7
- 02.49 *J Theor Biol* 265 :493-500;
- 02.47 *Malaria Journal* 5:82 doi:10.1186/1475-2875-5-82.
- 02.18 *Amer J Trop Med Hyg* 84: 3-4; 83:258-65; 81:587-94;75:155-61; 71:723-31; 70:20-6; 66:516-25; 65:685-9; 58:630-7; 58:625-9; 52: 347-8; 50: 646-53,200-5;49: 485-91,473-7,121-6,113-20; 48: 377-84,126-33; 46:169-82; 45:98-111; 44:553-9; 40:7-11; 39:15-20; 38:24-9; 36:9-14; 36:1-2;35:472-5
- 02.02 *J Biomed Sci* 9 :34-40
- 02.00 *Acta Trop* 95: 183-93.
- 01.92 *Trans Roy Soc Trop Med Hyg* 87: 81-3; 86: 123-6; 85: 33-4; 84: 474-8; 88: 691-6; 83:308-10
- 01.70 *Parasitol* 134: 1151-62
- 01.60 *Exper Parasitol* 87: 283-9; 76: 345-51; 72: 450-8; 67: 354-60; 87: 283-289
- 01.51 *Parasitol Research*: 100:141-8. 100: .
- 01.35 *Ann Trop Med Parasitol*: 97: 439-5187: 547-52; 100:571-8
- 01.33 *J Travel Med* 7: 275-282
- 01.13 *Prog Clin Parasitol* 1: 21-56
- 01.08 *Euro J Med Chem* 39: 59-67.
- 00.54 *J Serbian Chem* 72: 1181-90; 69: 919-922; 68: 291-302
- 00.37 *Military Med*: 170: 2-12; 154: 55-59
- 00.09 *Heterocycles* 31: 1011

Publications Sorted by Date

1. Gargano LM, Engel J, Gray GC, Howell K, Jones TF, Milhous WK, Morris JG, Mead, DG, Rubin C, Unnasch TR, Woods CW and Hughes JM. 2013. Arbovirus Diseases.

- Southeastern United States. *Emerg Infect Dis* Volume 19, Number 11—November 2013 [Internet]. <http://dx.doi.org/10.3201/eid1911.130650>
2. Serebrennikova YM, Patel J, Milhous WK, Garcia-Rubio LH, Huffman DE, Smith JM. Spectrophotometric detection of susceptibility to anti-malarial drugs. *Malar J*. 2013 Aug 30;12:305. doi: 10.1186/1475-2875-12-305. PubMed PMID: 23992478; PubMed Central PMCID: PMC3849014.
 3. Perić M, Fajdetić A, Rupčić R, Alihodžić S, Zihher D, Bukvić Krajačić M, Smith KS, Ivezić-Schönfeld Z, Padovan J, Landek G, Jelić D, Hutinec A, Mesić M, Ager A, Ellis WY, **Milhous WK**, Ohrt C, Spaventi R. Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin. *J Med Chem*. 2012 Feb 9;55(3):1389-401. Epub 2012 Jan 25. PubMed PMID: 22148880.
 4. Gargano LM, Gallagher PF, Freeman AS, Morris JG Jr, Temporado Cookson S, Greenwald I, **Milhous WK**, Williams-Johnson M, Wolfe C, Isakov A, Woods CW and Hughes, JM Academic consortia: untapped resources for preparedness, response, and recovery—examining the cholera outbreak in Haiti. *Emerg Infect Dis* [serial on the Internet] Vol 17 No. 11. 2011 Nov. wwwnc.cdc.gov/eid/article/17/11/11-0727.htm
 5. Dow GS, Gettayacamin M, Hansukjariya P, Imerbsin R, Komcharoen S, Sattabongkot J, Kyle D, **Milhous W**, Cozens S, Kenworthy D, Miller A, Veazey J, Ohrt C. Radical curative efficacy of tafenoquine combination regimens in *Plasmodium cynomolgi*-infected Rhesus monkeys (*Macaca mulatta*). *Malar J*. 2011 Jul 29;10:212. PubMed PMID: 21801400; PubMed Central PMCID: PMC3161915.
 6. Bukvić Krajačić M, Perić M, Smith KS, Schönfeld ZI, Žihher D, Fajdetić A, Kujundžić N, Schönfeld W, Landek G, Padovan J, Jelić D, Ager A, **Milhous WK**, Ellis W, Spaventi R, Ohrt C. Synthesis, structure-activity relationship, and antimalarial activity of ureas and thioureas of 15-membered azalides. *J Med Chem*. 2011 May 26;54(10):3595-605. Epub 2011 May 4. PubMed PMID: 21476508.
 7. Hutinec A, Rupčić R, Zihher D, Smith KS, **Milhous W**, Ellis W, Ohrt C, Schönfeld ZI. An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics. *Bioorg Med Chem*. 2011 Mar 1;19(5):1692-701. Epub 2011 Jan 22. PubMed PMID: 21316974.
 8. Kazura JW, Ripp J, **Milhous WK**. Back to the future: the American Society of Tropical Medicine and Hygiene, its journal and the continuing commitment to global health. *Am J Trop Med Hyg*. 2011 Jan;84(1):3-4. PubMed PMID: 21212193; PubMed Central PMCID: PMC3005509.
 9. Gutteridge CE, Hoffman MM, Bhattacharjee AK, **Milhous WK**, Gerena L. In vitro efficacy of 7-benzylamino-1-isoquinolinamines against *Plasmodium falciparum* related to the efficacy of chalcones. *Bioorg Med Chem Lett*. 2011 Jan 15;21(2):786-9. Epub 2010 Nov 26. PubMed PMID: 21168330.
 10. Chattopadhyay R, Velmurugan S, Chakiath C, Andrews Donkor L, **Milhous W**, Barnwell JW, Collins WE, Hoffman SL. Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of *Plasmodium vivax* malaria. *PLoS One*. 2010 Dec 9;5(12):e14275. PubMed PMID: 21151554; PubMed Central PMCID: PMC3000326.
 11. Serebrennikova YM, Patel J, **Milhous WK**, García-Rubio LH. Quantitative analysis of morphological alterations in *Plasmodium falciparum* infected red blood cells through theoretical interpretation of spectral measurements. *J Theor Biol*. 2010 Jun 1. [Epub ahead of print] PubMed PMID: 20685319.
 12. Whitman TJ, Coyne PE, Magill AJ, Blazes DL, Green MD, **Milhous WK**, Burgess TH, Freilich D, Tasker SA, Azar RG, Endy TP, Clagett CD, Deye GA, Shanks GD, Martin GJ. An outbreak of *Plasmodium falciparum* malaria in U.S. Marines deployed to Liberia. *Am J Trop*

- Med Hyg. 2010 Aug;83(2):258-65. PubMed PMID: 20682864; PubMed Central PMCID: PMC2911167.
13. **Milhous WK** and Weina PJ. 2010. Speeding the botanical solution to malaria. *Science*. 2010 Jan 15;327(5963):279-80.
 14. Obaldia N, **Milhous W**, Kyle D. 2009. Adaptation of a Multidrug Resistant C2A Clone of *Plasmodium falciparum* from Thailand to Aotus Monkeys and its Preliminary in vivo Antimalarial Drug Resistance Profile. *Am J Trop Med Hyg*. 2009 Oct;81(4):587-94. PMID: 19815871
 15. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, **Milhous W**, Wirth DF, Oduola AM. Selection of *Plasmodium falciparum* multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. *Antimicrob Agents Chemother*. 2009 Mar;53(3):888-95. PubMed PMID: 19075074
 16. Mui EJ, Schiehser GA, **Milhous WK**, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R. 2009. Target Validation and Efficacy of a Novel Third Generation Antifolate Antimalarial Against Toxoplasmosis. *Memorias do Instituto Oswaldo Cruz*
 17. Šolaja BA, Opsenica D, Smith KS, **Milhous WK**, Terzić N, Opsenica I, Burnett JC, Nuss J, Gussio R, Bavari S. Novel 4-Aminoquinolines Active against Chloroquine-Resistant and Sensitive *P. falciparum* Strains that also Inhibit Botulinum Serotype A. *J Med Chem*. 51:4388-4391 2008 Jul 19. [Epub ahead of print]
 18. Opsenica I, Opsenica D, Lanteri CA, Anova L, **Milhous WK**, Smith KS, Solaja BA. New chimeric antimalarials with 4-aminoquinoline moiety linked to a tetraoxane skeleton. *J Med Chem*. 2008 Oct 9;51(19):6216-9. Epub 2008 Sep 6. PMID: 18774792 [PubMed - indexed for MEDLINE]
 19. Opsenica I, Opsenica D, Smith KS, **Milhous WK**, Solaja BA. Chemical Stability of the Peroxide Bond Enables Diversified Synthesis of Potent Tetraoxane Antimalarials. *J Med Chem*. 2008 Apr 10;51(7):2261-6. Epub 2008 Mar 11.
 20. Mui EJ, Schiehser GA, **Milhous WK**, Hsu H, Roberts CW, Kirisits M, Muench S, Rice D, Dubey JP, Fowble JW, Rathod PK, Queener SF, Liu SR, Jacobus DP, McLeod R. Novel Triazine JPC-2067-B Inhibits *Toxoplasma gondii* In Vitro and In Vivo. *PLoS Negl Trop Dis*. 2008 Mar 5;2(3):e190. PMID: 18320016
 21. Li Q, Weina PJ and **Milhous WK**. 2007. Pharmacokinetic and pharmacodynamic profiles of rapid-acting astemisinins in antimalarial therapy. *Current Drug Therapy* 2:210-223
 22. Guan J, Wang X, Smith K, Ager A, Gettayacamin M, Kyle DE, **Milhous WK**, Kozar MP, Magill AJ, Lin AJ. Malaria causal prophylactic activity of imidazolidinedione derivatives. *J Med Chem*. 2007 Nov 29;50(24):6226-31. Epub 2007 Oct 30. PMID: 17967003
 23. Opsenica I, Opsenica D, Jadranin M, Smith K, **Milhous WK**, Stratakis M and Šolaja B. 2007. On peroxide antimalarials. *J Serb Chem Soc* 72: 1181–1190.
 24. Diaz DS, Kozar MP, Smith KS, Asher CO, Sousa JC, Schiehser GA, Jacobus DP, **Milhous WK**, Skillman DR, Shearer TW. The role of specific P450 isoforms in the conversion of phenoxypropoxybiguanide analogs in human liver microsomes to potent antimalarial dihydrotriazines. *Drug Metab Dispos*. 2007 Drug Metab Dispos. 2008 Feb;36(2):380-5. Epub 2007 Nov 15.
 25. Terzić N, Opsenica D, Milić D, Tinant B, Smith KS, **Milhous WK**, Solaja BA. Deoxycholic acid-derived tetraoxane antimalarials and antiproliferatives. *J Med Chem*. 2007 Oct 18;50(21):5118-27. Epub 2007 Sep 21. PMID: 17887664
 26. Li Q, Kozar MP, Shearer TW, Xie LH, Lin AJ, Smith KS, Si Y, Anova L, Zhang J, **Milhous WK**, Skillman DR. Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinediamines administered in single and multiple doses in rats. *Antimicrob Agents Chemother*. 2007 Aug;51(8):2898-904. Epub 2007 Jun 11. PMID: 17562804

27. Xie L, Li Q, Johnson J, Zhang J, **Milhous W**, Kyle D. Development and validation of flow cytometric measurement for parasitaemia using autofluorescence and YOYO-1 in rodent malaria. *Parasitology*. 2007 Aug;134:1151-62. Epub 2007 Apr 20. PMID: 17445324
28. Li Q, Kozar MP, Shearer TW, Xie LH, Lin AJ, Smith KS, Si Y, Anova L, Zhang J, **Milhous WK**, Skillman DR. Pharmacokinetics, safety, and hydrolysis of oral pyrroloquinazolinodiamines administered in single and multiple doses in rats. *Antimicrob Agents Chemother*. 2007 Aug;51(8):2898-904. Epub 2007 Jun 11. PMID: 17562804
29. Li Q, Gerena L, Xie L, Zhang J, Kyle D, **Milhous W**. Development and validation of flow cytometric measurement for parasitemia in cultures of *P. falciparum* vitally stained with YOYO-1. *Cytometry A*. 2007 Feb 5; [Epub ahead of print] PMID: 17279569
30. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Bolaji OM, Fateye BA, Kyle DE, **Milhous W**, Wirth DF, Oduola AM. Linkage disequilibrium between two distinct loci in chromosomes 5 and 7 of *Plasmodium falciparum* and in vivo chloroquine resistance in Southwest Nigeria. *Parasitol Res*. 2006 Dec;100(1):141-8. Epub 2006 Jul 28. PMID: 16874478
31. Happi CT, Gbotosho GO, Folarin OA, Milner D, Sarr O, Sowunmi A, Kyle DE, **Milhous WK**, Wirth DF, Oduola AM. Confirmation of emergence of mutations associated with atovaquone-proguanil resistance in unexposed *Plasmodium falciparum* isolates from Africa. *Malar J*. 2006 Oct 4;5:82. PMID: 17020611
32. Gbotosho GO, Ogundahunsi OA, Happi CT, Kyle DE, Gerena L, **Milhous WK**, Sowunmi A, Oduola AM, Salako LA. The effects of alpha1-acid glycoprotein on the reversal of chloroquine resistance in *Plasmodium falciparum*. *Ann Trop Med Parasitol*. 2006 Oct;100(7):571-8. PMID: 16989682
33. Li Qigui, Milhous W and Weina PJ 2006: Fatal neurotoxicity of the artemisinin derivatives is related to drug pharmacokinetic profiles in animal species. *Current Topics in Toxicology* 3: 1-16.
34. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, **Milhous W**, Wirth DF, Oduola AM. Association between mutations in *Plasmodium falciparum* chloroquine resistance transporter and *P. falciparum* multidrug resistance 1 genes and in vivo amodiaquine resistance in *P. falciparum* malaria-infected children in Nigeria. *Am J Trop Med Hyg*. 2006 Jul;75(1):155-61. PMID: 16837724
35. Opsenica I, Terzic N, Opsenica D, Angelovski G, Lehnig M, Eilbracht P, Tinant B, Juranic Z, Smith KS, Yang YS, Diaz DS, Smith PL, **Milhous WK**, Dokovic D, Solaja BA. Tetraoxane antimalarials and their reaction with Fe(II). *J Med Chem*. 2006 Jun 29;49(13):3790-9. PMID: 16789736
36. Mui EJ, Jacobus D, **Milhous WK**, Schiehser G, Hsu H, Roberts CW, Kirisits MJ, McLeod R. Triazine Inhibits *Toxoplasma gondii* Tachyzoites In Vitro and In Vivo. *Antimicrob Agents Chemother*. 2005 Aug;49(8):3463-7. PMID: 16048961
37. Zhang Q, Guan J, Sacci J, Ager A, Ellis W, **Milhous W**, Kyle D, Lin AJ. Unambiguous synthesis and prophylactic antimalarial activities of imidazolidinedione derivatives. *J Med Chem*. 2005 Oct 6;48(20):6472-81.
38. Happi CT, Gbotosho GO, Folarin OA, Akinboye DO, Yusuf BO, Ebong OO, Sowunmi A, Kyle DE, **Milhous W**, Wirth DF, Oduola AM. Polymorphisms in *Plasmodium falciparum* dhfr and dhps genes and age related in vivo sulfadoxine-pyrimethamine resistance in malaria-infected patients from Nigeria. *Acta Trop*. 2005 Jul 14; PMID: 16023986
39. Shearer TW, Kozar MP, O'neil MT, Smith PL, Schiehser GA, Jacobus DP, Diaz DS, Yang YS, **Milhous WK**, Skillman DR. In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines. *J Med Chem*. 2005 Apr 21;48(8):2805-13.
40. Ockenhouse CF, Magill A, Smith DC, **Milhous WK**. 2005. History of US Military Contributions to the Study of Malaria. *Military Med* 170:12-16.

41. Guan J, Zhang Q, Montip G, Karle JM, Ditusa CA, **Milhous WK**, Skillman DR, Lin AJ. 2005. Structure identification and prophylactic antimalarial efficacy of 2-guanidinoimidazolidinedione derivatives. *Bioorg Med Chem.* 1;13(3):699-704. PMID: 15653337
42. Happi CT, Gbotosho GO, Sowunmi A, Falade CO, Akinboye DO, Gerena L, Kyle DE, **Milhous W**, Wirth DF, Oduola AM. Molecular analysis of *Plasmodium falciparum* recrudescence malaria infections in children treated with chloroquine in Nigeria. *Am J Trop Med Hyg.* 2004 Jan;70(1):20-6.
43. Bhattacharjee AK, Hartell MG, Nichols DA, Hick RP, Stanton B, van Hamont JE, **Milhous WK**. 2004. Structure-activity relationship study of antimalarial indolo [2,1-b]quinazoline-6,12-diones (tryptanthrins). Three dimensional pharmacophore modeling and identification of new antimalarial candidates. *Euro J Med Chem* 39: 59–67.
44. Opsenica I, Terzić N, Opsenica D, **Milhous WK**, Šolaja B. 2004. 7, 8,15,16-tetraoxa-dispiro[5.2.5.2] hexadecane-3-carboxylic acid derivatives and their antimalarial activity. *J Serb Chem Soc* 69: 919-922.
45. Li Q, Lugt CB, Looareesuwan S and **Milhous WK**. 2004. Pharmacokinetic investigation of the therapeutic potential of artemotil (beta-arteether) in Thai patients with severe *Plasmodium falciparum* malaria *Am J Trop Med Hyg* 71:723-731.
46. Roberts CW, Roberts F, Henriques FL, Akisoshi D, Samuel BU, Richards TA, **Milhous W**, Kyle D, McIntosh L, Hill, GC, Chaudhuri M, Tzipori and McLeod R. 2004. Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite *Cryptosporidium parvum*: a potential anti-microbial agent target. *International J Parasitol* 34: 297-308.
47. Opsenica D, Kyle DE, **Milhous WK**, Šolaja BA. 2003. Antimalarial, antimycobacterial and antiproliferative activity of phenyl substituted mixed tetraoxanes *J Serbian Chem Soc* 68: 291-302
48. Happi TC, Thomas SM, Gbotosho GO, Falade CO, Akinboye DO, Gerena L, Hudson T, Sowunmi A, Kyle DE, **Milhous W**, Wirth DF, Oduola AM. Point mutations in the *pfprt* and *pfmdr-1* genes of *Plasmodium falciparum* and clinical response to chloroquine, among malaria patients from Nigeria. *Ann Trop Med Parasitol.* 2003 Jul;97(5):439-51. PMID: 12930607
49. Opsenica D, Angelovski G, Pocsfalvi G, Juranic Z, Zizak Z, Kyle D, **Milhous WK**, Solaja BA. 2003. Antimalarial and antiproliferative evaluation of Bis-Steroidal tetraoxanes. *Bioorg Med Chem.* 2003 Jul 3;11(13):2761-8.
50. Li QG, Mog SR, Si YZ, Kyle DE, Gettayacamin M, **Milhous WK**. Neurotoxicity and efficacy of arteether related to its exposure times and exposure levels in rodents. *Am J Trop Med Hyg.* 2002 May;66(5):516-25.
51. Solaja BA, Terzic N, Pocsfalvi G, Gerena L, Tinant B, Opsenica D, **Milhous WK**. Mixed steroidal 1,2,4,5-tetraoxanes: antimalarial and antimycobacterial activity. *J Med Chem.* 2002 Aug 1;45(16):3331-6.
52. Bhattacharjee AK, Kyle DE, Vennerstrom JL, **Milhous WK**. A 3D QSAR pharmacophore model and quantum chemical structure activity analysis of chloroquine(CQ)-resistance reversal. *J Chem Inf Comput Sci.* 2002 Sep-Oct;42(5):1212-20.
53. Riel MA, Kyle DE, Bhattacharjee AK, **Milhous WK**. Efficacy of proton pump inhibitor drugs against *Plasmodium falciparum* in vitro and their probable pharmacophores. *Antimicrob Agents Chemother.* 2002 Aug;46(8):2627-32.
54. Ohrt C, Willingmyre GD, Lee P, Knirsch C, **Milhous W**. Assessment of azithromycin in combination with other antimalarial drugs against *Plasmodium falciparum* in vitro. *Antimicrob Agents Chemother.* 2002 Aug;46(8):2518-24.
55. Guan J, Kyle DE, Gerena L, Zhang Q, **Milhous WK**, Lin AJ. Design, synthesis, and evaluation of new chemosensitizers in multi-drug-resistant *Plasmodium falciparum*. *J Med Chem.* 2002 Jun 20;45(13):2741-8.

56. Riel MA, Kyle DE, **Milhous WK**. Efficacy of scopadulcic acid A against *Plasmodium falciparum* in vitro. *J Nat Prod*. 2002 Apr;65(4):614-5.
57. Opsenica D, Pocsfalvi G, **Milhous WK**, Solaja BA. 2002. Antimalarial peroxides: the first intramolecular 1,2,3,5-tetroxane *J Serb Chem Soc* 67(7) 265-471.
58. Roberts CW, Roberts F, Lyons RE, Kirisits MJ, Mui EJ, Finnerty J, Johnson JJ, Ferguson DJ, Coggins JR, Krell T, Coombs GH, **Milhous WK**, Kyle DE, Tzipori S, Barnwell J, Dame JB, Carlton J, McLeod R. The shikimate pathway and its branches in apicomplexan parasites. *J Infect Dis*. 2002 Feb 15;185 Suppl 1:S25-36. Review.
59. Dietze R, Carvalho SF, Valli LC, Berman J, Brewer T, **Milhous W**, Sanchez J, Schuster B, Grogl M. 2001. Phase 2 trial of WR6026, an orally administered 8-aminoquinoline, in the treatment of visceral leishmaniasis caused by *Leishmania chagasi*. *Am J Trop Med Hyg*. 2001 Dec;65(6):685-9. PMID: 11791957
60. **Milhous WK**. 2001. Development of new drugs for prophylaxis of malaria. *Med Trop (mars)* 61: 48-50.
61. Iyer JK, **Milhous WK**, Cortese JF, Kublin JG, Plowe CV. 2001. *Plasmodium falciparum* cross-resistance between trimethoprim and pyrimethamine. *Lancet*. 2001 Sep 29;358(9287):1066-7.
62. Si YZ, Li QG, Mog SR and **Milhous WK**. 2001. Neurotoxic mechanism study of arteether and artemisinin acid in rats with microdialysis. *Am J Trop Med Hyg* 65(3): 221 (2001).
63. Zhang P, Nicholson, Bujnicki JM, Su X, Brendle J, Ferdig M, Kyle, DE, **Milhous WK** and Chiang PK. 2001. Angiogenesis inhibitors specific for aminopeptidase 2 as drugs for malaria and leishmania. *J BioMed Sci* 1: 34-40.
64. McLeod R, Muench SP, Rafferty JB, Kyle DE, Mui EJ, Kirisits MJ, Mack DG, Roberts CW, Samuel BU, Lyons RE, Dorris M, **Milhous WK**, Rice DW. 2001. Triclosan inhibits the growth of *Plasmodium falciparum* and *Toxoplasma gondii* by inhibition of Apicomplexan Fab I. *International J Parasitol* 31: 109-113.
65. Opsenica D, Pocsfalvi G, Juranic Z, Tinant B, Declercq JP, Kyle DE, **Milhous WK**, Solaja BA. 2000. Cholic acid derivatives as 1,2,4,5-tetraoxane carriers: structure and antimalarial and antiproliferative activity. *J Med Chem*. Aug 24;43(17):3274-82. PMID: 10966746; UI: 20425068
66. Jefford CW, Rosier, J-C and **Milhous WK**. 2000. Trioxanes, 1,2,4,5-tetroxanes and bicyclic endoperoxides. Implications for mode of action. *Heterocycles* 52: 1335-1353.
67. Vennerstrom JL, Dong Y, Andersen SL, Ager AL, Fu H-H, Miller RE, Miller, Wesche DL, Kyle DE, Gerena G, Walters SM, Wood JK, Edwards G, Holme AD, McLean WG, and **Milhous WK**. 2000. Synthesis and antimalarial activity of sixteen dispiro-1,2,4,5-tetraoxane analogs of WR148999: Alkyl substituted 7,8,15,16-tetraoxadispiro[5.2.5.2] hexadecanes. *J. Med. Chem.* 43(14), 2753-2758.
68. Sanchez JL, Bendet J, Grogl, Peira-Lima JB, Pang LW, Guimaraes R, Guedes RH, Abreu DG, **Milhous WK**, Green MD, Todd GD. 2000. Malaria morbidity among Brazilian military personnel deployed to Angola. *J Travel Med* 7: 275-282.
69. McCullough KJ, Wood JK, Bhattacharjee AK, Dong Y, Kyle DE, **Milhous WK**, Vennerstrom JL. Methyl-substituted dispiro-1,2,4,5-tetraoxanes: correlations of structural studies with antimalarial activity. *J Med Chem*. 2000 Mar 23;43(6):1246-9. PMID: 10737758; UI: 20202366
70. Walsh DS, Loareesuwan S, Wilairatana P, Heppner DG Jr, Tang DB, Brewer TG, Chokejindachai W, Viriyavejakul P, Kyle DE, **Milhous WK**, Schuster BG, Horton J, Braitman DJ, Brueckner RP. Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of *Plasmodium vivax* malaria in Thailand. *J Infect Dis*. 1999 Oct;180(4):1282-7. PMID: 10479159; UI: 99408853
71. Vennerstrom JL, Nuzum EO, Miller RE, Dorn A, Gerena L, Dande PA, Ellis WY, Ridley RG, **Milhous WK**. 8-Aminoquinolines active against blood stage *Plasmodium falciparum* in vitro

- inhibit hematin polymerization. *Antimicrob Agents Chemother.* 1999 Mar;43(3):598-602. PMID: 10049273; UI: 99169761
72. Vennerstrom JL, Ager AL Jr, Dorn A, Andersen SL, Gerena L, Ridley RG, **Milhous WK**. Bisquinolines. 2. Antimalarial N,N-bis (7-chloroquinolin-4-yl) heteroalkane-diamines. *J Med Chem.* 1998. Oct 22;41(22):4360-4. PMID: 9784111; UI: 99000699
 73. Jefford CW, Jaggi D, Kohmoto S, Timári G, Bernardinelli G, Canfield CJ, **Milhous WK** 1998. The structure and antimalarial activity of some cis-fused bicyclic 1,2,4-trioxane derivatives. *Heterocycles* 49 (1), pp. 375-383
 74. Roberts F, Roberts CW, Johnson JJ, Kyle DE, Krell T, Coggins JR, Coombs GH, **Milhous WK**, Tzipori S, Ferguson DJ, Chakrabarti D, McLeod R. Evidence for the shikimate pathway in apicomplexan parasites. *Nature.* 1998 Jun 25;393(6687):801-5. PMID: 9655396; UI: 98318102
 75. Zalis MG, Pang L, Silveira MS, **Milhous WK**, Wirth DF. Characterization of *Plasmodium falciparum* isolated from the Amazon region of Brazil: evidence for quinine resistance. *Am J Trop Med Hyg.* 1998 May;58(5):630-7. PMID: 9598453; UI: 98258400
 76. Oduola AM, Sowunmi A, **Milhous WK**, Brewer TG, Kyle DE, Gerena L, Rossan RN, Salako LA, Schuster BG. *In vitro* and *in vivo* reversal of chloroquine resistance in *Plasmodium falciparum* with promethazine. *Am J Trop Med Hyg.* 1998 May;58(5):625-9. PMID: 9598452; UI: 98258399
 77. Roberts F, Roberts CW, Johnson JJ, **Milhous WK**, Kyle D, Tzipori S, Ferguson D, McLeod R. 1999. The shikimate pathway in apicomplexan parasites. *Nature* 397: 219-220.
 78. Makler M, Piper RC, **Milhous WK**. 1998. Parasite lactate dehydrogenase and the diagnosis of malaria. *Parasitology Today* 14: 376-377.
 79. DeAlcena, FEC, Junior CC, Durlacher RR, Boulos M, **Milhous WK**, Pang LW. 1997. Treatment of uncomplicated falciparum malaria with a combination of Atovaquone plus Proguanil in Brazilian adults. *J Inf Dis* 175-1544-47.
 80. Adami YL, **Milhous WK**, Daniel-Ribeiro Claudio T, Ferreira-da-Cruz M. 1998. *In vitro* antimalarial activity of crude extracts of *Phothomorphe peltata* and *P. umbellata* (Piperaceae). *Tropical Med* 40:91-94.
 81. Oduola AM, Omitowoju GO, Sowunmi A, Makler MT, Falade CO, Kyle DE, Fehintola FA, Ogundahunsi OA, Piper RC, Schuster BG, **Milhous WK**. *Plasmodium falciparum*: evaluation of lactate dehydrogenase in monitoring therapeutic responses to standard antimalarial drugs in Nigeria. *Exp Parasitol.* 1997 Nov;87(3):283-9. PMID: 9371095; UI: 98038429
 82. Grigorov M, Weber J, Tronchet JM, Jefford CW, **Milhous WK**, Maric D. A QSAR study of the antimalarial activity of some synthetic 1,2,4-trioxanes. *J Chem Inf Comput Sci.* 1997 Jan-Feb;37(1):124-30. PMID: 9025258; UI: 97177752
 83. Vasconcelos KF, Marques C, Silveira M S, Pang L, **Milhous WK**, Wirth DF, Plowe CV, Zalis MZ. 1997. Mutations in *Plasmodium falciparum* DHFR and DHPS of isolates from the Amazon Region of Brazil. *Memorias do Instituto Oswaldo Cruz* 92: 145.
 84. Avery MA, Bonk JD, Chong KM, Bonk JD, Mehrotra S, Miller R, **Milhous WK**, Goins DK, Venkatesan S, Wyandt C, Khan I, Avery BA. 1996. Structure-activity relationships of the antimalarial agent artemisinin. 2. Effect of heteroatom substitution at O-11: synthesis and bioassay of N-alkyl-11-aza-9-desmethylartemisinins. *J Med Chem.* 1995 Dec 22;38(26):5038-44. PMID: 8544180
 85. Posner GH, Chong HO, Gerena L, **Milhous WK**. 1995. Synthesis and antimalarial activities of structurally simplified 1,2,4-trioxanes related to artemisinin. *Heteroatom Chem* 6:103-105.
 86. **Milhous WK**, Zalis MG and Pang LW. 1995. New Prospects for Prophylaxis and Treatment of Malaria. 1995. *Canadian J Infect Dis* 6: 399.

87. Pang L, Alencar FE, Cerutti C Jr, **Milhous WK**, Andrade AL, Oliveira R, Kanesa-Thanan N, McCarthy PO, Hoke CH Jr. Short report: hepatitis E infection in the Brazilian Amazon. *Am J Trop Med Hyg.* 1995 Apr;52(4):347-8. PMID: 7741175; UI: 95259741
88. Cooper RD, **Milhous WK**, Rieckmann KH. The efficacy of WR238605 against the blood stages of a chloroquine resistant strain of *Plasmodium vivax*. *Trans R Soc Trop Med Hyg.* 1994 Nov-Dec;88(6):691-2. PMID: 7886774; UI: 95193045
89. Holfels E, McAuley J, Mack D, **Milhous WK**, McLeod R. *In vitro* effects of artemisinin ether, cycloguanil hydrochloride (alone and in combination with sulfadiazine), quinine sulfate, mefloquine, primaquine phosphate, trifluoperazine hydrochloride, and verapamil on *Toxoplasma gondii*. *Antimicrob Agents Chemother.* 1994 Jun;38(6):1392-6. PMID: 8092843; UI: 94379797
90. Coleman RE, Nath AK, Schneider I, Song GH, Klein TA, **Milhous WK**. Prevention of sporogony of *Plasmodium falciparum* and *P. berghei* in *Anopheles stephensi* mosquitoes by transmission-blocking antimalarials. *Am J Trop Med Hyg.* 1994 May;50(5):646-53. PMID: 8203716; UI: 94263001
91. Posner GH, Oh CH, Wang D, Gerena L, **Milhous WK**, Meshnick SR, Asawamahasadka W. Mechanism-based design, synthesis, and *in vitro* antimalarial testing of new 4-methylated trioxanes structurally related to artemisinin: the importance of a carbon-centered radical for antimalarial activity. *J Med Chem.* 1994 Apr 29;37(9):1256-8. PMID: 8176702; UI: 94231526
92. Basco LK, Andersen SL, **Milhous WK**, Le Bras J, Vennerstrom JL. *In vitro* activity of bisquinoline WR268,668 against African clones and isolates of *Plasmodium falciparum*. *Am J Trop Med Hyg.* 1994 Feb;50(2):200-5. PMID: 8116813; UI: 94161211
93. Avery MA, Gao F, Chong WK, Mehrotra S, **Milhous WK**. Structure-activity relationships of the antimalarial agent artemisinin. 1. Synthesis and comparative molecular field analysis of C-9 analogs of artemisinin and 10-deoxoartemisinin. *J Med Chem.* 1993 Dec 24;36(26):4264-75. PMID: 8277509; UI: 94104024
94. Peters W, Robinson BL, **Milhous WK**. The chemotherapy of rodent malaria. II. Studies on a new 8-aminoquinoline, WR 238,605. *Ann Trop Med Parasitol.* 1993 Dec;87(6):547-52. PMID: 8122915; UI: 94168467
95. Cabral JA, McChesney JD, **Milhous WK**. A new antimalarial quassinoid from *Simaba guianensis*. *J Nat Prod.* 1993 Nov;56 (11):1954-61. PMID: 8289064; UI: 94118037
96. Maeno Y, Toyoshima T, Fujioka H, Ito Y, Meshnick SR, Benakis A, **Milhous WK**, Aikawa M. Morphologic effects of artemisinin in *Plasmodium falciparum*. *Am J Trop Med Hyg.* 1993 Oct;49(4):485-91. PMID: 8214279; UI: 94027578
97. Corcoran KD, Hansukjariya P, Sattabongkot J, Ngampochjana M, Edstein MD, Smith CD, Shanks GD, **Milhous WK**. Causal prophylactic and radical curative activity of WR182393 (a guanylhydrazone) against *Plasmodium cynomolgi* in *Macaca mulatta*. *Am J Trop Med Hyg.* 1993 Oct;49(4):473-7. PMID: 8214277; UI: 94027576
98. Canfield CJ, **Milhous WK**, Ager AL, Rossan RN, Sweeney TR, Lewis NJ, Jacobus DP. PS-15: a potent, orally active antimalarial from a new class of folic acid antagonists. *Am J Trop Med Hyg.* 1993 Jul;49(1):121-6. PMID: 8352384; UI: 93356292
99. De D, Bhaduri AP, **Milhous WK**. A novel pyrrolidonoalkaneamine (WR268954) that modulates chloroquine resistance of *Plasmodium falciparum in vitro*. *Am J Trop Med Hyg.* 1993 Jul;49(1):113-20. PMID: 8352383; UI: 93356291
100. Karle JM, Olmeda R, Gerena L, **Milhous WK**. *Plasmodium falciparum*: role of absolute stereochemistry in the antimalarial activity of synthetic amino alcohol antimalarial agents. *Exp Parasitol.* 1993 Jun;76(4):345-51. PMID: 8513873; UI: 93292620
101. Shmuklarsky MJ, Klayman DL, **Milhous WK**, Kyle DE, Rossan RN, Ager AL Jr, Tang DB, Heiffer MH, Canfield CJ, Schuster BG. Comparison of beta-artemether and beta-artether against malaria parasites *in vitro* and *in vivo*. *Am J Trop Med Hyg.* 1993 Mar;48(3):377-84. PMID: 8470775; UI: 93228179

102. Oduola AM, Omitowoju GO, Gerena L, Kyle DE, **Milhous WK**, Sowunmi A, Salako LA. Reversal of mefloquine resistance with penfluridol in isolates of *Plasmodium falciparum* from south-west Nigeria. *Trans R Soc Trop Med Hyg.* 1993 Jan-Feb;87(1):81-3. PMID: 8465407; UI: 93220127.
103. Jefford CW, Velarde JA, Bernardinelli G, Bray DH, Warhurst DC and **Milhous WK**. 1993. Synthesis, structure and antimalarial activity of tricyclic 1,2,4-trioxanes related to artemisinin. In: *Helvetica chimica acta.* - Basel. - Vol. 76(1993), p. 2775-2788.
104. Kyle DE, **Milhous WK**, Rossan RN. Reversal of *Plasmodium falciparum* resistance to chloroquine in Panamanian Aotus monkeys. *Am J Trop Med Hyg.* 1993 Jan;48(1):126-33. PMID: 8427381; UI: 93151369
105. Wilson CM, Volkman SK, Thaithong S, Martin RK, Kyle DE, **Milhous WK**, Wirth DF. Amplification of pfm_{dr} 1 associated with mefloquine and halofantrine resistance in *Plasmodium falciparum* from Thailand. *Mol Biochem Parasitol.* 1993 Jan;57(1):151-60. PMID: 8426608; UI: 93149200
106. Gerena L, Bass GT Sr, Kyle DE, Oduola AM, **Milhous WK**, Martin RK. Fluoxetine hydrochloride enhances *in vitro* susceptibility to chloroquine in resistant *Plasmodium falciparum*. *Antimicrob Agents Chemother.* 1992 Dec; 36 (12):2761-5. PMID: 1482144; UI: 93128890
107. Vennerstrom JL, Fu HN, Ellis WY, Ager AL Jr, Wood JK, Andersen SL, Gerena L, **Milhous WK**. Dispiro-1,2,4,5-tetraoxanes: a new class of antimalarial peroxides. *J Med Chem.* 1992 Aug 7;35(16):3023-7. PMID: 1501229; UI: 92365045
108. Karle JM, Karle IL, Gerena L, **Milhous WK**. Stereochemical evaluation of the relative activities of the cinchona alkaloids against *Plasmodium falciparum*. *Antimicrob Agents Chemother.* 1992 Jul;36(7):1538-44. PMID: 1510452; UI: 92378254
109. Posner GH, Oh CH, Gerena L, **Milhous WK**. Extraordinarily potent antimalarial compounds: new, structurally simple, easily synthesized, tricyclic 1,2,4-trioxanes. *J Med Chem.* 1992 Jun 26;35(13):2459-67. PMID: 1619620; UI: 92318215
110. Vennerstrom JL, Ellis WY, Ager AL Jr, Andersen SL, Gerena L, **Milhous WK**. Bisquinolines. 1. N,N-bis(7-chloroquinolin-4-yl)alkanediamines with potential against chloroquine-resistant malaria. *J Med Chem.* 1992 May 29;35(11):2129-34. PMID: 1597862; UI: 92284489
111. Antoun MD, Gerena L and **Milhous WK**. 1993. Screening of the flora of Puerto Rico for potential antimalarial bioactives. *Int. J. Pharmacog.* 31:255-258
112. Schuster BG and **Milhous WK** 1993. Reduced resources applied to antimalarial drug development. *Parasitol. Today* 9: 167-168.
113. Casteel DA, Jung KE, Gerena L, **Milhous W**. 1992. Synthesis and antimalarial evaluation of 2,3,5-trioxabicyclo[2.2.2]octanes, models for the putative pharmacophore of qinghaosu (artemisinin). *Bioorganic Med Chem Letters* 2: 623-626
114. Toyoshima, T. Fujioka, H., Maeno, Y., Meschnick, S. A. Benakis, **Milhous, WK**. And M. Aikawa. 1993. Morphological effects of artemisinin in *Plasmodium falciparum*, *Amer. J. Trop. Med. Hyg.* 49: 485-491.
115. Oduola AM, Sowunmi A, **Milhous WK**, Kyle DE, Martin RK, Walker O, Salako LA. Innate resistance to new antimalarial drugs in *Plasmodium falciparum* from Nigeria. *Trans R Soc Trop Med Hyg.* 1992 Mar-Apr ;86(2):123-6. PMID: 1440764; UI: 93069394
116. Coleman RE, Clavin AM, **Milhous WK**. Gametocytocidal and sporontocidal activity of antimalarials against *Plasmodium berghei ANKA* in ICR mice and *Anopheles stephensi* mosquitoes. *Am J Trop Med Hyg.* 1992 Feb;46(2):169-82. PMID: 1539752; UI: 92171052

117. Grogl M, Martin RK, Oduola AM, **Milhous WK**, Kyle DE. Characteristics of multidrug resistance in Plasmodium and Leishmania: detection of P-glycoprotein-like components. *Am J Trop Med Hyg.* 1991 Jul;45(1):98-111. PMID: 1678253; UI: 91328346
118. Childs GE, Boudeau EF, Wimonwattratee T, Pang L, **Milhous WK**. *In vitro* and clinical correlates of mefloquine resistance of *Plasmodium falciparum* in eastern Thailand. *Am J Trop Med Hyg.* 1991 May;44(5):553-9. PMID: 2063958; UI: 91290164
119. Li J, Zhu JD, Appiah A, McCutchan TF, Long GW, **Milhous WK**, Hollingdale MR. Plasmodium berghei: quantitation of *in vitro* effects of antimalarial drugs on exoerythrocytic development by a ribosomal RNA probe. *Exp Parasitol.* 1991 May;72(4):450-8. PMID: 2026219; UI: 91224251
120. Bartlett MS, Queener SF, Tidwell RR, **Milhous WK**, Berman JD, Ellis WY, Smith JW. 8-Aminoquinolines from Walter Reed Army Institute for Research for treatment and prophylaxis of Pneumocystis pneumonia in rat models. *Antimicrob Agents Chemother.* 1991 Feb;35(2):277-82. PMID: 2024961; UI: 91221597
121. Willet GP, **Milhous WK**, Gerena L, Oduola AM. Mixed population dynamics in human malaria parasite cultures. *Trans R Soc Trop Med Hyg.* 1991 Jan-Feb;85(1):33-4. No abstract available. PMID: 2068751; UI: 91297713
122. Kyle DE, Oduola AM, Martin SK, **Milhous WK**. *Plasmodium falciparum*: modulation by calcium antagonists of resistance to chloroquine, desethylchloroquine, quinine, and quinidine *in vitro*. *Trans R Soc Trop Med Hyg.* 1990 Jul-Aug;84(4):474-8. PMID: 2091331; UI: 91220364
123. Jung M, Li X, Bustos DA, elSohly HN, McChesney JD, **Milhous WK**. Synthesis and antimalarial activity of (+)-deoxoartemisinin. *J Med Chem.* 1990 May;33(5):1516-8. PMID: 2329574; UI: 90230261
124. Chang HO and **Milhous WK**. 1992. Olefin oxidative cleavage and dioxethane formation using triethylsilyl hydrotrioxide: applications to preparation of potent antimalarial 1,2,4-trioxanes. *Tetrahedron Letters* 32:4235-4238.
125. Imakura Y, Hachiya K, Ikemoto, t., Yamashita S, Kihara M, Kobayashi S, Shingu T, **Milhous WK** and Lee K-H. 1990. Acid degradation products of qinghaosu and their structure-activity relationship. *Heterocycles*, Vol 31: 1011.
126. Kelley PW, Takafuji ET, Weiner PJ, **Milhous WK**, Miller R, Thompson L, Schantz P. and Miller, RE. 1989. An outbreak of hookworm infection associated with military operations in Grenada. *Military Med.* 154: 55-59.
127. Peterson DS, **Milhous WK**, Wellems TE. Molecular basis of differential resistance to cycloguanil and pyrimethamine in *Plasmodium falciparum* malaria. *Proc Natl Acad Sci U S A.* 1990 Apr;87(8):3018-22. PMID: 2183222; UI: 90222161
128. Rathod PK, Khatri A, Hubbert T, **Milhous WK**. Selective activity of 5-fluoroorotic acid against *Plasmodium falciparum in vitro*. *Antimicrob Agents Chemother.* 1989 Jul;33(7):1090-4. PMID: 2675756; UI: 89391375
129. Oduola AM, Moyou-Somo RS, Kyle DE, Martin SK, Gerena L, **Milhous WK**. Chloroquine resistant *Plasmodium falciparum* in indigenous residents of Cameroon. *Trans R Soc Trop Med Hyg.* 1989 May-Jun;83(3):308-10. PMID: 2694461; UI: 90141785
130. **Milhous WK**, Gerena L, Kyle DE, Oduola AM. *In vitro* strategies for circumventing antimalarial drug resistance. *Prog Clin Biol Res.* 1989;313:61-72. PMID: 2675118; UI: 89387193
131. Childs GE, Boudreau EF, **Milhous WK**, Wimonwattratee T, Pooyindee N, Pang L, Davidson DE Jr. A comparison of the *in vitro* activities of amodiaquine and desethylamodiaquine against isolates of *Plasmodium falciparum*. *Am J Trop Med Hyg.* 1989 Jan;40(1):7-11. PMID: 2644858; UI: 89132928
132. Scheibel LW, Colombani PM, Hess AD, Aikawa M, Atkinson CT, Igarashi I, Matsumoto Y, **Milhous WK**. Calcium/calmodulin functions in *P. falciparum in vitro*-

- implications for antiprotozoal drug design. *Prog Clin Parasitol.* 1989;1:21-56. Review. PMID: 2491694; UI: 91370901
133. Bitonti AJ, Sjoerdsma A, McCann PP, Kyle DE, Oduola AM, Rossan RN, **Milhous WK**, Davidson DE Jr. Reversal of chloroquine resistance in malaria parasite *Plasmodium falciparum* by desipramine. *Science.* 1988 Dec 2;242(4883):1301-3. PMID: 3057629; UI: 89058641
134. Oduola AM, **Milhous WK**, Weatherly NF, Bowdre JH, Desjardins RE. *Plasmodium falciparum*: induction of resistance to mefloquine in cloned strains by continuous drug exposure *in vitro*. *Exp Parasitol.* 1988 Dec;67(2):354-60. PMID: 3056740; UI: 89052827
135. Jacobs GH, Oduola AM, Kyle DE, **Milhous WK**, Martin SK, Aikawa M. Ultrastructural study of the effects of chloroquine and verapamil on *Plasmodium falciparum*. *Am J Trop Med Hyg.* 1988 Jul;39(1):15-20. PMID: 3041853; UI: 88292554
136. Oduola AM, **Milhous WK**, Salako LA, Walker O, Desjardins RE. Reduced *in vitro* susceptibility to mefloquine in West African isolates of *Plasmodium falciparum*. *Lancet.* 1987 Dec 5;2(8571):1304-5. PMID: 2890904; UI: 88064693
137. Krogstad DJ, Gluzman IY, Kyle DE, Oduola AM, Martin SK, **Milhous WK**, Schlesinger PH. Efflux of chloroquine from *Plasmodium falciparum*: mechanism of chloroquine resistance. *Science.* 1987 Nov 27;238(4831):1283-5. PMID: 3317830; UI: 88070584
138. Lin AJ, Klayman DL, **Milhous WK**. Antimalarial activity of new water-soluble dihydroartemisinin derivatives. *J Med Chem.* 1987 Nov;30(11):2147-50. PMID: 3669021; UI: 88035946
139. Childs GE, Hausler B, **Milhous WK**, Chen C, Wimonwantrrawte T, Poooyindee N, Boudreau EF. 1988. *In vitro* activity of pyronaridine against *Plasmodium falciparum*. *Am. J. Trop. Med. Hyg.* 38: 24-29.
140. Brossi A, Venuogopalan B, Dominguez Gerpe L, Yeh HLS, Flippen-Anderson JL, Buch P, Luo XG, **Milhous WK** and Peters W. 1988. Arteether, a new antimalarial drug: synthesis and antimalarial properties. *J. Med. Chem.* 31: 645-650.
141. Scheibel LW, Colombani PM, Hess AD, Aikawa M, Atkinson CT, **Milhous WK**. Calcium and calmodulin antagonists inhibit human malaria parasites (*Plasmodium falciparum*): implications for drug design. *Proc Natl Acad Sci U S A.* 1987 Oct;84(20):7310-4. PMID: 3313391; UI: 88041097
142. Martin SK, Oduola AM, **Milhous WK**. Reversal of chloroquine resistance in *Plasmodium falciparum* by verapamil. *Science.* 1987 Feb 20;235(4791):899-901. PMID: 3544220; UI: 87120334
143. Jacobs GH, Aikawa M, **Milhous WK**, Rabbege JR. An ultrastructural study of the effects of mefloquine on malaria parasites. *Am J Trop Med Hyg.* 1987 Jan;36(1):9-14. PMID: 3544894; UI: 87125512
144. Pierce PF, **Milhous WK**, Campbell CC. Clinical and laboratory characterization of a chloroquine-resistant *Plasmodium falciparum* strain acquired in the Central African Republic. *Am J Trop Med Hyg.* 1987 Jan;36(1):1-2. PMID: 3544889; UI: 87125486
145. Campbell CC, Collins WE, **Milhous WK**, Roberts JM, Armstead A. Adaptation of the Indochina I/CDC strain of *Plasmodium falciparum* to the squirrel monkey (*Saimiri sciureus*). *Am J Trop Med Hyg.* 1986 May;35(3):472-5. PMID: 3518503; UI: 86212820
146. **Milhous WK**, Weatherly NF, Bowdre JH, Desjardins RE. *In vitro* activities of and mechanisms of resistance to antifol antimalarial drugs. *Antimicrob Agents Chemother.* 1985 Apr;27(4):525-30. PMID: 3890727; UI: 85224042

147. Daddona PE, Wiesmann WP, **Milhous WK**, Chern J, Townsend LB, Ershfield MS and Webster HK 1986. Expression of human malaria parasite purine nucleoside phosphorylase in host enzyme-deficient erythrocyte culture. Enzyme characterization and identification of novel inhibitors. *J Biol Chem.* 1986 Sep 5;261(25):11667-73. PMID: 3091593.
148. Klayman DL, Lin AJ, Acton N, Scovill JP, Hoch JM, Milhous WK, Theoharides AD, Dobek AS. Isolation of artemisinin (qinghaosu) from *Artemisia annua* growing in the United States. *J Nat Prod.* 1984 Jul-Aug;47(4):715-7. PMID: 6387056; UI: 85032758
149. Milhous W, Solis J. Ultrastructure of *Leucocytozoon smithi* gametocytes. *Poult Sci.* 1973 Nov;52(6):2138-46. PMID: 4207749

Books, Book Chapters & Reviews

150. **Milhous, W K** (2008) Globalizations, Volume 5, Issue 4 December 2008 , pages 621 - 629, Book Review: *Medicine at the Border: Disease, Globalization, and Security, 1850 to the Present.* <http://dx.doi.org/10.1080/14747730802528407>
151. Li Q, **Milhous WK** and Weina PJ. 2007. *Artemisinins in Malaria Therapy.* Nova Science Publishers, Inc. Hauppauge, Inc NY.
152. Apurba K. Bhattacharjee, Mark G. Hartell, Daniel A. Nichols, Rickey P. Hicks, John E. van Hamont, **Wilbur K. Milhous.** 2006. In *Silico Three Dimensional Pharmacophore Models to Aid the Discovery and Design of New Antimalarial Agents*, Lecture Notes in Computer Science, Volume 3991, Apr 2006, Pages 387 – 394. Qigui Li;
153. Olliaro P and **Milhous WK.** 2001. The antimalarial portfolio and research pipeline. In: *Antimalarial Chemotherapy: Mechanisms of Action, Resistance and New Directions in Drug Discovery.* Rosenthal [ed], The Humana Press, Inc., NJ, 219-232.
154. Brueckner RP, Baird K, Ohrt C and **Milhous WK.** 2001. 8-Aminoquinolines in Antimalarial Chemotherapy: Modes of action, mechanisms of resistance, and new directions in drug development, Rosenthal [ed], The Humana Press, Inc., NJ. 123-151.
155. Schuster BG, Jackson JE, Obijiofor CN, Okunji CO, **Milhous WK**, Losos E, Ayafor JF, Iwu MM, 2000. Drug development and conservation of biodiversity in West and Central Africa: a model for collaboration. *Pharmaceutical Biology* 37(Supplement):1-16.
156. **Milhous WK** and Kyle DE. 1998. Antimalarial Drugs: Modes of Action and Mechanisms of Resistance. In: *Malaria: Parasite Biology, Pathogenesis, Protection.* Amer Soc of Microbiology, IW Sherman ed. pp 301-316.
157. Jefford CW, Misra D, Rossier C-C, Makalaprija P, Burger U, Mareda J, Bernardinella, Peters W, Robinson BL, **Milhous WK**, Zhang F, Gosser DK, and Meshnick SR. Cyclopenteno-1,2,4-trioxanes as effective antimalarial surrogates of artemisinin. 1993. In: *Perspectives in medicinal chemistry.* - Basel : Verlag Helvetica chimica acta 459-472.
158. **Milhous WK**, Gerena L Kyle, DE, Miller RE, Nuzum EO, Martin RK, Webster HK, Oduola AMJ. 1996. The global spread of multiple drug resistant malaria: clinical, epidemiological and theoretical implications. In: *Migration of infectious diseases: 500 years after Columbus*, Alan T. Evangelista (ed), Plenum Press, NY
159. Angerhofer CK, Konig GM, Wright AD, Stocher O, **Milhous WK**, Cordell GA, Farnsworth N and Pezzuto JM. Selective screening of natural products: a resource for the discovery of novel antimalarial compounds. In: *Atta-ur-Rahman, ed, Advances in Natural Product Chemistry*, Harwood Academic Publishers, Chur, Switzerland, 1992, pp 311-329.
160. **Milhous WK** and Geary TG. 1991. Drug discovery and development. In: *Malaria Obstacles and Opportunities.* pp. 144-168. Eds. S. C. Oaks, V. S. Mitchell, G.W. Pearson & C. J. Carpenter, Washington, National Academy Press.

Curriculum Vitae, Wil Milhous, 2014

161. **Milhous WK** and Schuster BG. 1990. Malaria studies aim at drug resistance. U.S. Medicine 26: 27-28
162. Vennerstrom JL, Eaton JW, Ellis WY and **Milhous WK**. 1991. Antimalarial Synergism and Antagonism. In: Molecular Mechanisms and Chemotherapeutic Synergism, Potentiation & Antagonism. pp. 183-222. Eds. Ting Chau Chou & Darryl C. Rideout, Orlando, Academic Press.
163. **Milhous WK**, Klayman, DL and Davidson, DE. 1986. Antimalarial activity of artemisinin & its derivatives. WHO. TDR/CHEMAL/ART 86.3: 12 17.
164. Whaun J, Brown N, **Milhous W**, Lambros C, Scovill J, Lin AJ, Klayman DL. 1985. Qinghaosu, a potent antimalarial, perturbs polyamine metabolism in human malaria cultures. In: Polyamine: Basic and clinical aspects, pp 301-310, Imahori et al., (eds), VNU Science